Scientific Opinion on Flavouring Group Evaluation 200 (FGE.200): 74 α,β-unsaturated aldehydes and precursors from subgroup 1.1.1 of FGE.19 by EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF)
   EFSA Journal 2014;12(6):3709 
 
Suggested citation: EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids), 
2014. Scientific Opinion on Flavouring Group Evaluation 200 (FGE.200): 74 α,β-unsaturated aldehydes and precursors from 
subgroup 1.1.1 of FGE.19. EFSA Journal 2014;12(6):3709, 57 pp. doi:10.2903/j.efsa.2014.3709 
Available online: www.efsa.europa.eu/efsajournal  
© European Food Safety Authority, 2014 
 
SCIENTIFIC OPINION 
 Scientific Opinion on Flavouring Group Evaluation 200 (FGE.200): 74 α,β-
unsaturated aldehydes and precursors from subgroup 1.1.1 of FGE.19
1 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)
2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
This scientific output, published on 04 August 2014, replaces the earlier version published on 12 June 
2014*. 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to evaluate the genotoxic potential of 74 flavouring substances from subgroup 1.1.1 of 
FGE.19 in the Flavouring Group Evaluation 200 (FGE.200). The Flavour Industry has provided additional 
genotoxicity studies for one representative substance in FGE.200, namely hex-2(trans)-enal [FL-no 05.073], and 
for other two substances in the same subgroup, namely 2-dodecenal [05.037] and 2-nonenal [05.171]. The Panel 
has evaluated these data and concluded that the concern still remains with respect to genotoxicity for the 
substances of this subgroup and their three representative substances. The Panel confirms, the need for an in vivo 
Comet assay performed in duodenum and liver for hex-2(trans)-enal [FL-no: 05.073]. For the two other 
representative substances of subgroup 1.1.1 (nona-2(trans),6(cis)-dienal [FL-no: 05.058] and oct-2-enal [FL-no: 
05.060]), a combined in vivo Comet assay and micronucleus assay would be required. For the latter, evidence of 
bone marrow exposure should be provided. 
© European Food Safety Authority, 2014 
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SUMMARY 
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was asked to evaluate flavouring substances using the 
Procedure as referred to in the Commission Regulation (EC) No 1565/2000.  
The present Flavouring Group Evaluation 200 (FGE.200) concerns 74 substances, corresponding to 
subgroup 1.1.1 of FGE.19. These substances are 74 straight chain, α,β-unsaturated aldehydes, with or 
without additional non-conjugated double-bonds, or precursors for such structures. 
Information on one representative material hex-2(trans)-enal [FL-no: 05.073] and two other 
substances, 2-nonenal [FL-no: 05.171] and 2-dodecenal [FL-no: 05.037] from subgroup 1.1.1, has now 
been submitted by the European Flavour Association. This information is intended to cover the re-
evaluation of the above mentioned substances and of the following 71 substances from FGE.19 
subgroup 1.1.1. 
The new data submitted are related only to one representative substance of subgroup 1.1.1, hex-
2(trans)-enal [FL-no: 05.073]. 
For hex-2(trans)-enal [FL-no: 05.073] gene mutations were observed in vitro  in TA100,  and 
chromosomal aberrations were observed in vitro likewise. In addition, a biomonitoring study in human 
buccal cells showed a statistically significant increase in the frequency of micronuclei at 
concentrations that might be relevant for the use of hex-2(trans)-enal as flavouring substance. The 
new submitted study performed on a Muta
TMMouse model does not cover these endpoints adequately. 
The Panel noted that overall the available experimental data from animals and humans, while not 
showing an induction of gene mutations, do not allow to assess the potential clastogenic activity of 
hex-2(trans)-enal at the first site of contact and in the liver where higher levels of DNA adducts were 
observed than in other tissues investigated. Therefore, the new data provided by the Industry do not 
rule out the genotoxicity concern for the substances of subgroup 1.1.1. 
For both 2-dodecenal and 2-nonenal tested through micronucleus assays in mouse bone marrow PCE 
(Honarvar, 2007b; Honarvar, 2008) there was no direct confirmation that the bone marrow was 
exposed, as no toxicokinetic measures of the test substance in plasma were made. 
Under these conditions, the Panel confirms the need for an  in vivo  Comet assay  performed in 
duodenum and liver for hex-2(trans)-enal [FL-no: 05.073]. For the two other representative substances 
of subgroup 1.1.1 (nona-2(trans),6(cis)-dienal [FL-no: 05.058] and oct-2-enal [FL-no: 05.060]), a 
combined in vivo Comet assay and micronucleus assay would be required. For the latter, evidence of 
bone marrow exposure should be provided.  Flavouring Group Evaluation 200 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The use of flavouring is regulated under Regulation (EC) No 1334/2008
4 of the European Parliament 
and Council of 16 December 2008 on flavourings and certain food ingredients with flavouring 
properties for use in and on foods. On the basis of article 9(a) of this Regulation an evaluation and 
approval are required for flavouring substances. 
The Union List of flavourings and source materials was established by Commission Implementing 
Regulation (EC) No 872/2012
5. The list contains flavouring substances for which the scientific 
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/2000
6. 
In the 26
th  Plenary meeting of the AFC Panel on 27-29 November 2007, EFSA discussed the 
flavouring group evaluation 19 (FGE.19). FGE.19 contains those flavouring substances which are α,β-
unsaturated aldehydes or ketones and their precursors which could give rise to such carbonyl 
substances  via  hydrolysis  and/or  oxidation.  The  α,β-unsaturated aldehyde and ketone structure is 
considered by the Panel to be a structural alert for genotoxicity. FGE.19 was divided into subgroups. 
For subgroup 1.1.1 EFSA concluded that there is a need for additional information before conclusions 
on the substances in this subgroup can be reached. On 21 February 2011, EFSA adopted a statement 
on earlier data provided by the European Flavour Association concerning this subgroup. However, the 
conclusion was that the need for additional genotoxicity data had not been alleviated and genotoxicity 
studies should be carried out for the representative substances. 
Information on one representative material hex-2(trans)-enal [FL-no: 05.073] and two other 
substances, 2-nonenal [FL-no: 05.171] and 2-dodecenal [FL-no: 05.037] from subgroup 1.1.1, has now 
been submitted by the European Flavour Association. This information is intended to cover the re-
evaluation of the above mentioned substances and of the following 71 substances from FGE.19 
subgroup 1.1.1: 
•  Hex-2-en-1-ol [FL-no: 02.020] 
•  Nona-2,6-dien-1-ol [FL-no: 02.049] 
•  Pent-2-en-1-ol [FL-no: 02.050] 
•  Non-2(trans)-en-1-ol [FL-no: 02.090] 
•  Non-2(cis)-en-1-ol [FL-no: 02.112] 
•  Dec-2-en-1-ol [FL-no: 02.137] 
•  Hex-2(cis)-en-1-ol [FL-no: 02.156] 
•  Oct-2-en-1-ol [FL-no:02.192] 
•  Undec-2-en-1-ol [FL-no: 02.210] 
•  Tr-2, cis-6-Nonadien-1-ol [FL-no: 02.231] 
•  2-Dodecenal [FL-no: 05.037] 
•  Nona-2(trans),6(cis)-dienal [FL-no: 05.058] 
•  Oct-2-enal [FL-no: 05.060] 
•  2-Heptenal [FL-no: 05.070] 
•  trans-2-Nonenal [FL-no: 05.072] 
•  Hex-2(trans)-enal [FL-no: 05.073] 
•  Dec-2-enal [FL-no: 05.076] 
•  Tridec-2-enal [FL-no: 05.078] 
                                                       
4  Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and 
certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 
1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34-50. 
5  EC (European Commission), 2012. Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting 
the list of flavouring substances provided for by Regulation (EC) No 2232/96 of the European Parliament and of the 
Council, introducing it in Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council and 
repealing Commission Regulation (EC) No 1565/2000 and Commission Decision 1999/217/EC.OJ L 267, 2.10.2012, p. 1. 
6  Commission Regulation (EC) No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an 
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8-16. Flavouring Group Evaluation 200 
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•  Pent-2-enal [FL-no: 05.102] 
•  2-Undecenal [FL-no: 05.109] 
•  Octa-2(trans),6(trans)-dienal [FL-no: 05.111] 
•  4-Methylpent-2-enal [FL-no: 05.114] 
•  Dodeca-2,6-dienal [FL-no: 05.120] 
•  Dodec-2(trans)-enal [FL-no: 05.144] 
•  Hept-2(trans)-enal [FL-no: 05.150] 
•  2-Nonenal [FL-no: 05.171] 
•  Nona-2(trans),6(trans)-dienal [FL-no: 05.172] 
•  Tetradec-2-enal [FL-no: 05.179] 
•  Undec-2(trans)-enal [FL-no: 05.184] 
•  2-Hexenal [FL-no: 05.189] 
•  trans-2-Octenal [FL-no: 05.190] 
•  trans-2-Decenal [FL-no: 05.191] 
•  trans-2-Tridecenal [FL-no: 05.195] 
•  1,1-Diethoxynona-2,6-diene [FL-no: 06.025] 
•  1,1-Diethoxyhex-2-ene [FL-no: 06.031] 
•  1,1-Dimethoxyhex-2(trans)-ene [FL-no: 06.072] 
•  Allyl butyrate [FL-no: 09.054] 
•  Allyl heptanoate [FL-no: 09.097] 
•  Allyl nonanoate [FL-no: 09.109] 
•  Allyl octanoate [FL-no: 09.119] 
•  Allyl undec-10-enoate [FL-no: 09.146] 
•  Allyl propionate [FL-no: 09.233] 
•  Allyl hexanoate [FL-no: 09.244] 
•  Allyl crotonate [FL-no: 09.247] 
•  Oct-2-enyl acetate [FL-no: 09.276] 
•  Oct-2(trans)-enyl butyrate [FL-no: 09.277] 
•  Hept-2-enyl isovalerate [FL-no: 09.303] 
•  Allyl hexa-2,4-dienoate [FL-no: 09.312] 
•  Hept-2-enyl acetate [FL-no: 09.385] 
•  Hex-2(trans)-enyl acetate [FL-no: 09.394] 
•  Hex-2(trans)-enyl propionate [FL-no: 09.395] 
•  Hex-2-enyl butyrate [FL-no: 09.396] 
•  Hex-2-enyl formate [FL-no: 09.397] 
•  Hex-2-enyl hexanoate [FL-no: 09.398] 
•  Hex-2-enyl isovalerate [FL-no: 09.399] 
•  Hex-2-enyl phenylacetate [FL-no: 09.400] 
•  Allyl 2-ethylbutyrate [FL-no: 09.410] 
•  Allyl cyclohexanebutyrate [FL-no: 09.411] 
•  Allyl cyclohexanevalerate [FL-no: 09.469] 
•  Allyl cyclohexaneacetate [FL-no: 09.482] 
•  Allyl isovalerate [FL-no: 09.489] 
•  Allyl cyclohexanehexanoate [FL-no: 09.492] 
•  Allyl 2-methylcrotonate [FL-no: 09.493] 
•  Allyl cyclohexanepropionate [FL-no: 09.498] 
•  Pent-2-enyl hexanoate [FL-no: 09.678] 
•  Allyl phenoxyacetate [FL-no: 09.701] 
•  Allyl anthranilate [FL-no: 09.719] 
•  Allyl cinnamate [FL-no: 09.741] 
•  Allyl phenylacetate [FL-no: 09.790] Flavouring Group Evaluation 200 
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•  2-Hexenyl octanoate [FL-no: 09.841] 
•  Allyl valerate [FL-no: 09.866] 
•  (E,Z)-2,6-Nonadienyl acetate [FL-no: 09.947] 
•  (2E)-2-Nonenyl acetate [FL-no: 09.948] 
•  Allyl 2-furoate [FL-no: 13.004]. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION  
The European Commission requests the European Food Safety Authority to carry out a safety 
assessment on the following 74 substances: hex-2-en-1-ol [FL-no: 02.020], nona-2,6-dien-1-ol [FL-no: 
02.049], pent-2-en-1-ol [FL-no: 02.050], non-2(trans)-en-1-ol [FL-no: 02.090], non-2(cis)-en-1-ol 
[FL-no: 02.112], dec-2-en-1-ol [FL-no: 02.137], hex-2(cis)-en-1-ol [FL-no: 02.156], oct-2-en-1-ol 
[FL-no:02.192], undec-2-en-1-ol [FL-no: 02.210], tr-2, cis-6-nonadien-1-ol [FL-no: 02.231], 2-
dodecenal [FL-no: 05.037], nona-2(trans),6(cis)-dienal [FL-no: 05.058], oct-2-enal [FL-no: 05.060], 2-
heptenal [FL-no: 05.070], trans-2-nonenal [FL-no: 05.072], hex-2(trans)-enal [FL-no: 05.073], dec-2-
enal [FL-no: 05.076], tridec-2-enal [FL-no: 05.078], pent-2-enal [FL-no: 05.102], 2-undecenal [FL-no: 
05.109], octa-2(trans),6(trans)-dienal [FL-no: 05.111], 4-methylpent-2-enal [FL-no: 05.114], dodeca-
2,6-dienal [FL-no: 05.120], dodec-2(trans)-enal [FL-no: 05.144], hept-2(trans)-enal [FL-no: 05.150], 
2-nonenal [FL-no: 05.171], nona-2(trans),6(trans)-dienal [FL-no: 05.172], tetradec-2-enal [FL-no: 
05.179], undec-2(trans)-enal [FL-no: 05.184], 2-hexenal [FL-no: 05.189], trans-2-octenal [FL-no: 
05.190], trans-2-decenal [FL-no: 05.191], trans-2-tridecenal [FL-no: 05.195], 1,1-diethoxynona-2,6-
diene [FL-no: 06.025], 1,1-diethoxyhex-2-ene [FL-no: 06.031], 1,1-dimethoxyhex-2(trans)-ene [FL-
no: 06.072], allyl butyrate [FL-no: 09.054], allyl heptanoate [FL-no: 09.097], allyl nonanoate [FL-no: 
09.109], allyl octanoate [FL-no: 09.119], allyl undec-10-enoate [FL-no: 09.146], allyl propionate [FL-
no: 09.233], allyl hexanoate [FL-no: 09.244], allyl crotonate [FL-no: 09.247], oct-2-enyl acetate [FL-
no: 09.276], oct-2(trans)-enyl butyrate [FL-no: 09.277], hept-2-enyl isovalerate [FL-no: 09.303], allyl 
hexa-2,4-dienoate [FL-no: 09.312], hept-2-enyl acetate [FL-no: 09.385], hex-2(trans)-enyl acetate 
[FL-no: 09.394], hex-2(trans)-enyl propionate [FL-no: 09.395], hex-2-enyl butyrate [FL-no: 09.396], 
hex-2-enyl formate [FL-no: 09.397], hex-2-enyl hexanoate [FL-no: 09.398], hex-2-enyl isovalerate 
[FL-no: 09.399], hex-2-enyl phenylacetate [FL-no: 09.400], allyl 2-ethylbutyrate [FL-no: 09.410], 
allyl cyclohexanebutyrate [FL-no: 09.411], allyl cyclohexanevalerate [FL-no: 09.469], allyl 
cyclohexaneacetate [FL-no: 09.482], allyl isovalerate [FL-no: 09.489], allyl cyclohexanehexanoate 
[FL-no: 09.492], allyl 2-methylcrotonate [FL-no: 09.493], allyl cyclohexanepropionate [FL-no: 
09.498], pent-2-enyl hexanoate [FL-no: 09.678], allyl phenoxyacetate [FL-no: 09.701], allyl 
anthranilate [FL-no: 09.719], allyl cinnamate [FL-no: 09.741], allyl phenylacetate [FL-no: 09.790], 2-
hexenyl octanoate [FL-no: 09.841], allyl valerate [FL-no: 09.866], (E,Z)-2,6-nonadienyl acetate [FL-
no: 09.947], (2E)-2-nonenyl acetate [FL-no: 09.948] and allyl 2-furoate [FL-no: 13.004] in accordance 
with Commission Regulation (EC) No 1565/2000. Flavouring Group Evaluation 200 
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HISTORY OF FGE.19 
Flavouring Group Evaluation 19 (FGE.19) contains 360 flavouring substances from the EU Register 
being α,β-unsaturated aldehydes or ketones and precursors which could give rise to such carbonyl 
substances via hydrolysis and / or oxidation (EFSA, 2008a). 
The α,β-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity. The Panel 
noted that there were limited genotoxicity data on these flavouring substances but that positive 
genotoxicity studies were identified for some substances in the group. 
The α,β-unsaturated carbonyls were subdivided into subgroups on the basis of structural similarity 
(EFSA, 2008a). In an attempt to decide which of the substances could go through the Procedure, a 
(quantitative) structure-activity relationship (Q)SAR prediction of the genotoxicity of these substances 
was undertaken considering a number of models (DEREKfW, TOPKAT, DTU-NFI-MultiCASE 
Models and ISS-Local Models, (Gry et al., 2007)). 
The Panel noted that for most of these models internal and external validation has been performed, but 
considered that the outcome of these validations was not always extensive enough to appreciate the 
validity of the predictions of these models for these alpha, beta- unsaturated carbonyls. Therefore, the 
Panel considered it inappropriate to totally rely on (Q)SAR predictions at this point in time and 
decided not to take substances through the procedure based on negative (Q)SAR predictions only. 
The Panel took note of the (Q)SAR predictions by using two ISS Local Models (Benigni and Netzeva, 
2007a; Benigni and  Netzeva, 2007b)  and four DTU-NFI MultiCASE Models (Gry et al., 2007; 
Nikolov et al., 2007) and the fact that there are available data on genotoxicity, in vitro and in vivo, as 
well as data on carcinogenicity for several substances. Based on these data the Panel decided that 15 
subgroups (1.1.1, 1.2.1, 1.2.2, 1.2.3, 2.1, 2.2, 2.3, 2.5, 3.2, 4.3, 4.5, 4.6, 5.1, 5.2 and 5.3) (EFSA, 
2008a) could not be evaluated through the Procedure due to concern with respect to genotoxicity. 
Corresponding to these subgroups, 15 Flavouring Group Evaluations (FGEs) were established: 
FGE.200, 204, 205, 206, 207, 208, 209, 211, 215, 219, 221, 222, 223, 224 and 225. 
For 11 subgroups the Panel decided, based on the available genotoxicity data and (Q)SAR predictions, 
that a further  scrutiny of the data should take place before requesting additional data from the 
Flavouring Industry on genotoxicity. These subgroups were evaluated in FGE.201, 202, 203, 210, 212, 
213, 214, 216, 217, 218 and 220. For the substances in FGE.202, 214 and 218 it was concluded that a 
genotoxic potential could be ruled out and accordingly these substances will be evaluated using the 
Procedure. For all or some of the substances in the remaining FGEs, FGE.201, 203, 210, 212, 213, 
216, 217 and 220 the genotoxic potential could not be ruled out. 
To ease the data retrieval of the large number of structurally related α,β-unsaturated substances in the 
different subgroups for which additional data are requested, EFSA worked out a list of representative 
substances for each subgroup (EFSA, 2008c). Likewise an EFSA genotoxicity expert group has 
worked out a test strategy to be followed in the data retrieval for these substances (EFSA, 2008b).  
The Flavouring Industry has been requested to submit additional genotoxicity data according to the list 
of representative substances and test strategy for each subgroup.   
The Flavouring Industry has now submitted additional data and the present FGE concerns the 
evaluation of these data requested on genotoxicity. Flavouring Group Evaluation 200 
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ASSESSMENT 
1.  History of the Evaluation of the Substances in Subgroup 1.1.1 
Subgroup 1.1.1 is one of the FGE.19 subgroups for which the Panel concluded that additional 
genotoxicity data  are needed  to perform the  safety assessment of the genotoxic potential of the 
substances (EFSA, 2008a; EFSA CEF Panel, 2011). This conclusion was based on the in vitro and in 
vivo genotoxicity data available at that time as well as on the outcome of the (Q)SAR predictions (see 
Tables 6, 7 and 5, respectively).  
Hex-2(trans)-enal [FL-no: 05.073], nona-2(trans),6(cis)-dienal [FL-no: 05.058], oct-2-enal [FL-no: 
05.060] and 4,5-epoxydec-2(trans)-enal [FL-no: 16.071] were selected as representative substances to 
be tested for the subgroup 1.1.1 (EFSA, 2008c). The substance 4,5-epoxydec-2(trans)-enal [FL-no: 
16.071] was subsequently considered structurally different from the other substances in subgroup 1.1.1 
and was allocated to FGE.226 for evaluation on its own. The representative substances should be 
tested in accordance with the conditions set out in the “Genotoxicity Test Strategy for Substances 
belonging to Subgroups of FGE.19” (EFSA, 2008b). The representative substances for subgroup 1.1.1 
are shown in Table 1. 
Table 1:   Representative Substances for Subgroup 1.1.1 of FGE.19 (EFSA, 2008c) 
FL-no   EU Register name   Structural formula   Comments  
05.073  Hex-2(trans)-enal 
O  Data from literature and 
new study reports 
(Beevers, 2013; Bhatia et 
al., 2010; Dittberner et al., 
1995; Dittberner et al., 
1997; Durward, 2009; 
Eder et al., 1992; Griffin 
and Segall, 1986; 
Honarvar, 2007a; Kato et 
al., 1989; Sokolowski, 
2007a) 
05.058  Nona-2(trans),6(cis)-dienal 
O
 
Data from literature 
(Dittberner et al., 1995; 
Eder et al., 1992) 
05.060  Oct-2-enal 
O  Data from literature 
(Canonero et al., 1990; 
Eder et al, 1993; Marnett 
et al.,1985) 
 
In October 2009, the Industry submitted the first dossier in response to the requested data (this dossier 
was replaced by an updated dossier in April 2010, (EFFA, 2010)).  
The Panel considered these new data and its conclusion was given in an EFSA statement published in 
February 2011 (EFSA CEF Panel, 2011): 
“Supplementary information now provided includes both new data and arguments, which have been 
discussed by the Panel. Overall, the supplementary information provided by EFFA is not considered 
sufficient. Flavouring Group Evaluation 200 
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•  Although some of arguments provided by EFFA (e.g. those on metabolism and GSH-depletion and 
those on the role of DNA damage) are plausible, they are not sufficient to alleviate concerns for 
the genotoxic and carcinogenic potential of the substances belonging to subgroup 1.1.1. 
 
•  The data provided are not compliant with the “Genotoxicity Test Strategy for Substances in 
Subgroups of FGE.19”.  
 
Therefore, the need for additional genotoxicity data has not been alleviated and genotoxicity studies 
should be carried out for the representative substances of subgroup 1.1.1. In line with the Genotoxicity 
Test Strategy (EFSA 2008b), the Panel recommended to perform in vivo dietary Comet assays (in 
drinking water or in feed, not by gavage) for the three linear representatives of subgroup 1.1.1 [FL-
no: 05.073, 05.058 and 05.060]. The results may allow to identify whether there is a critical chain 
length for DNA damage.” 
 
The present Opinion on FGE.200 deals with the additional genotoxicity data submitted by the 
International Organization of the Flavor Industry (IOFI, 2013) in response to the EFSA statement on 
the first dossier submitted to EFSA on FGE.200. The data submitted are listed in Table 2.  
Furthermore, four additional flavouring substances (trans-2,cis-6-nonadien-1-ol  [FL-no: 02.231], 
undec-2(trans)-enal [FL-no: 05.184], trans-2-octenal [FL-no: 05.190] and trans-2-tridecenal [FL-no: 
05.195]) have been identified which are structurally related to the substances in subgroup 1.1.1 and 
should be evaluated within this group. 
2.  Presentation of the Substances Belonging to FGE.200 
The  Flavouring  Group  Evaluation  200  (FGE.200)  concerns  74  straight  chain,  α,β-unsaturated 
aldehydes, with or without additional non-conjugated double-bonds, or precursors for such structures. 
The 74 substances correspond to subgroup 1.1.1 of FGE.19. One former member of subgroup 1.1.1, 
4,5-epoxydec-2(trans)-enal [FL-no: 16.071], has been withdrawn from this subgroup and has been 
evaluated in a new FGE (FGE.226) as the Panel did not consider the substance to be sufficiently 
structurally  related to the other 74 substances in subgroup 1.1.1. The chemical structure of the 
substances are shown in Table 3 together with their specifications. 
3.  Additional Data Submitted by Industry for Subgroup 1.1.1  
In February 2011, the Panel evaluated the first dossier submitted by the Industry in response to the 
requested data for representative substances in FGE.200. These data were not considered adequate to 
alleviate the genotoxicity concern for the substance in subgroup 1.1.1 and concluded: “the Panel 
recommended to perform in vivo dietary Comet assays (in drinking water or in feed, not by gavage) 
for the three linear representatives of subgroup 1.1.1 [FL-no: 05.073, 05.058 and 05.060]”.  
In February and June 2013 the Industry (IOFI, 2013) submitted the second dossier which included 
additional data on one [FL-no: 05.073] of the three representative substances originally selected by the 
Panel and supporting information to the data already submitted in the first dossier. In Table 2 the 
newly submitted data are listed.   
FGE  Adopted by EFSA  Link  No. of 
Substances 
Statement on 
FGE.19 
subgroup 
1.1.1 
21 February 2011  http://www.efsa.europa.eu/en/efsajournal/pub/2086.htm  70 
FGE.200  21 May 2014  http://www.efsa.europa.eu/en/efsajournal/pub/3709.htm  74 Flavouring Group Evaluation 200 
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Table 2:   Overview of New Data Submitted for Subgroup 1.1.1   (IOFI, 2013) 
 
Test substance  Test  Test conditions  Reference 
Hex-2(trans)-enal [05.073] 
representative substance  
(purity: 98.2 %) 
 
O  
Bacterial 
reverse 
mutation assay 
S. typhimurium strains TA98, 
TA100, TA102, TA1535 and 
TA1537 with and without 
metabolic activation up to 5000 
μg/plate. 
Sokolowski, 
2007a; 
Bhatia et 
al.,2010 
In vivo 
Micronucleus 
assay 
Muta
TMMouse blood reticulocytes 
(days -1, 4 and 31) 
Treatment by oral gavage at doses 
of 120, 235 and 350 mg/kg bw/day 
for 28 days. 
Beevers, 
2013 
Induction of 
lacZ-mutations 
in 
Muta
TMMouse 
Muta
TMMouse treatment by oral 
gavage at doses of 120, 235 and 
350 mg/kg bw/day for 28 days. 
Mutation frequencies (day 31) 
determinated in the liver and the 
duodenum. 
Beevers, 
2013 
  In vivo 
Micronucleus 
assay 
Treatment by oral route at doses of 
250, 500, 1000 mg/kg bw/day. 
Sampling of bone marrow was 
done 24 and 48 hours after 
treatment. 
Honarvar, 
2007a 
  In vivo rat liver 
unscheduled 
DNA synthesis 
(UDS) assay 
Treatment by oral route at doses of 
200 and 500 mg/kg bw/day. Liver 
was perfused at 16 and 3 hours 
after dosing. 
Durward, 
2009 
2-Dodecenal [05.037]  
not representative  
(purity: 99.4 %) 
 
O 
Bacterial 
reverse 
mutation assay 
S. typhimurium strains TA98, 
TA100, TA102, TA1535 and 
TA1537 with and without 
metabolic activation up to 1000 
μg/plate.  
Sokolowski 
2007b; 
Bhatia et 
al.,2010 
In vivo 
Micronucleus  
assay 
Treatment by oral route at doses of 
500, 1000 and 2000 mg/kg 
bw/day. Sampling of bone marrow 
was done 24 and 48 hours after 
treatment. 2000 PCEs scored at 24 
hours (3 doses) and 48 hours (top 
dose). 
Honarvar, 
2007b; 
Bhatia et 
al.,2010 
2-Nonenal [05.171]  
not representative  
(purity: 96.2 %) 
 
O
(E)-isomer shown  
In vivo 
Micronucleus  
assay 
Treatment by oral route at doses of 
500, 1000 and 2000 mg/kg 
bw/day. Sampling of bone marrow 
was done 24 and 48 hours after 
treatment. 2000 PCEs scored at 24 
hours (3 doses) and 48 hours (top 
dose). 
Honarvar, 
2008; 
Bhatia et 
al.,2010 Flavouring Group Evaluation 200 
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3.1.  In vitro Genotoxicity Tests 
Bacterial reverse mutation assays 
Hex-2(trans)-enal [FL-no: 05.073] 
Hex-2(trans)-enal  (purity:  98.2  %)  was  tested  at  concentrations  up  to  5000  μg/plate  (but 
concentrations higher than 200 µg/plate were bacteriostatic) in the Salmonella typhimurium strains 
TA98, TA100, TA102, TA1535 and TA1537, in a GLP study performed according to OECD 
Guideline 471 (OECD, 1997a), with or without metabolic activation (Sokolowski, 2007a; Bhatia et al., 
2010). A small but concentration-dependent increase in revertant colony numbers was observed using 
the pre-incubation method in strain TA100 without metabolic activation (concentrations tested 1 - 
2500  μg/plate).  Toxic  effects  at  higher  concentrations  reduced  the  number  of  revertants.  Smaller 
increases (< 2-fold) were also seen in the presence of S9-mix. Therefore, a follow-up experiment, 
again using the pre-incubation method, was performed in strain TA100 over a narrow range of 
concentrations up to 200 μg/plate. In this follow-up experiment, a moderate concentration-dependent 
increase in revertant colony numbers was again observed without metabolic activation at 50 and 100 
µg/plate. Based on the reproducibility of this effect, the author concluded a positive mutagenic 
outcome for this test. While the magnitude of the increase in revertant colony numbers is not 
substantial, these results do not exclude possible mutagenic potential in strain TA100 (Sokolowski, 
2007a).  
Kato et al. (1989) tested hex-2(trans)-enal (unknown purity) in the S. typhimurium strains TA98, 
TA100, and TA104 and in Escherichia coli strain WP2uvrA/pKM101 with and without metabolic 
activation using the pre-incubation method (20 min at 37 °C). According to the authors, hex-2(trans)-
enal was ‘suspected to be positive’; however, no further details were provided and the validity of this 
study is limited. 
2-Dodecenal [FL-no: 05.037] 
At concentrations up to 1000 μg/plate with and without metabolic activation (but concentrations ≥ 100 
µg/plate were bacteriostatic) 2-dodecenal (purity: 99.4 %) was not mutagenic in the S. typhimurium 
strains TA98, TA100, TA102, TA1535 and TA1537, in a GLP study performed according to OECD 
Guideline 471; the limiting factor was the bacteriostatic activity (Sokolowski, 2007b). Toxic effects 
(reduction in revertant numbers) were seen at the higher concentrations in all parts of the study. No 
genotoxic effect was noted with and without metabolic activation in the five strains. 
The same data for the bacterial reverse mutation assay reported by Sokolowski (2007a, b) for hex-
2(trans)-enal [FL-no: 05.073] and 2-dodecenal [FL-no: 05.037] were presented in a poster abstract 
(Bhatia et al., 2010). 
Summary of the bacterial reverse mutation assays for both hex-2(trans)-enal [FL-no: 05.073] and 2-
dodecenal [FL-no: 05.037] are reported in Table 8. 
3.2.  In vivo Genotoxicity Tests 
Hex-2(trans)-enal [FL-no: 05.073] 
On the basis of the in vitro bacterial reverse mutation assay results reported above for hex-2(trans)-
enal, it was considered most appropriate to probe its genotoxic potential using a Muta™Mouse 
(lacZ/GalE) assay with an in vivo micronucleus component included (Beevers, 2013). The assay was 
carried out in transgenic mice. This combined approach minimises the number of animals used in the 
experiments. Micronuclei were measured in peripheral blood, and in the mutation arm of the 
experiment, the liver and the duodenum were chosen as the most appropriate tissues, in order to 
address the potential for mutation at the site of most significant metabolism and at the site of first 
contact, respectively. Therefore, groups of Muta™Mouse CD2-lacZ80/HazfBR mice were Flavouring Group Evaluation 200 
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administered  hex-2(trans)-enal  via gavage and the liver, duodenum and peripheral blood were 
analysed for the potential induction of DNA damage in a GLP study performed according to OECD 
Guidelines 474 (OECD, 1997b) and 488 (OECD, 2011). However, the Panel noted that there were 
some deviations from OECD guideline 474 (see below and Table 9). 
An initial Range-Finder study was conducted to estimate the maximum tolerated dose (MTD) of hex-
2(trans)-enal (purity 99.5 %) after administration by oral gavage to groups of three male and three 
female Muta™Mouse mice. Doses of 500 mg/kg body weight (bw)/day were clearly toxic to mice, 
with 1 animal being killed in extremis on day 4 and the rest of the animals exhibiting signs of toxicity 
(piloerection, hunched posture) but surviving to day 7. Further groups of animals were also dosed at 
250 and 350 mg/kg bw/day. No clinical signs of toxicity were observed at 250 mg/kg bw/day, but at 
350 mg/kg bw/day 1 animal showed signs of clinical toxicity (hunched posture, decreased activity and 
dyspnoea). As a result, 350 mg/kg bw/day was identified as the MTD. As no significant gender 
differences in clinical signs of toxicity were observed, it was concluded that male mice alone could be 
used in the main experiment. Two lower doses of 120 and 235 mg/kg bw/day were also selected for 
testing. 
Groups of six male Muta™Mouse mice were treated daily by oral gavage with hex-2(trans)-enal at 
doses of 120, 235 and 350 mg/kg bw/day, including a vehicle control (corn oil) for 28 days with a 3-
day recovery period prior to sacrifice. Concurrent positive control animals were not included in this 
study. Tissue matched positive control DNA was included in all packaging reactions in order to 
confirm correct assay functioning. The positive control DNA originated from animals dosed with 
ethylnitrosurea. All individual packaging reaction resulted in at least 30  000  plaque-forming unit 
(PFU) and at least 1 mutant plaque. For all animals data were generated for at least 200 000 PFU per 
tissue, from at least three independent packaging reactions. At least 1 million PFU were obtained per 
group, per tissue from a minimum of five animals. No significant increases in mutation frequency 
(MF) or significant dose-related trends were observed in the liver or the duodenum. Some of the hex-
2(trans)-enal treatment groups showed duodenum MF that exceeded laboratory historical controls but 
were comparable to concurrent vehicle control values. The testing laboratory had a limited number of 
datasets that comprise the historical control data for the duodenum in this assay and considered its 
historical control for the duodenum in the Muta
TMMouse assay to be narrow at the time of drafting this 
report. 
Hex-2(trans)-enal was evaluated in a micronucleus assay in peripheral normochromatic erythrocytes 
and reticulocytes for its ability to induce chromosomal damage (micronuclei, MN) in mice on days 4 
and 31 after 28 days of dosing, using a flow cytometry method. Where possible, 20 000 reticulocytes 
were analysed from each blood sample. No significant differences were observed in the frequency of 
peripheral blood reticulocytes (% RET) in all treatment groups on day 4 or 31 after 28 days of dosing. 
There were no significant increases in the frequency of micronuclei compared to concurrent controls 
on day 4 or 31 after 28 days of dosing. On day 31, it was noted that there was a significant linear trend 
in micronucleated reticulocyte  (%  MN-RET)  frequency  (P  ≤  0.05);  however, as  the MN-RET 
frequencies for all treated animals (0.37 + 0.04, 0.39 + 0.05, 0.39 + 0.06, 0.46 + 0.09 at doses of 0, 
120, 235, 350 mg/kg bw/day respectively) were highly consistent with the Day -1 background levels 
of MN-RET (0.38 + 0.04, 0.39 + 0.05, 0.41+ 0.05, 0.42+ 0.05, at doses of 0, 120, 235, 350 mg/kg 
bw/day respectively), the significant linear response was considered to be an artefact and was not 
indicative of any accumulation of micronuclei over time (Beevers, 2013). 
The Panel noted that in the micronucleus arm of the study, the peripheral blood was sampled 72 hours 
after the treatment while the OECD Guideline 474 recommends: ”once between 36 and 48 hours 
following the final treatment for the peripheral blood”. This point limited the reliability of the results 
obtained in the micronucleus part of the assay. 
Hex-2(trans)-enal  (purity: 98.2 %)  was evaluated in a micronucleus assay in bone marrow 
polychromatic erythrocytes (PCEs) for its ability to induce chromosomal damage (micronuclei, MN) 
in mice in a GLP study performed according to OECD Guideline 474 (OECD, 1997b). Hex-2(trans)-Flavouring Group Evaluation 200 
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enal dissolved in corn oil as a carrier was given orally to animals (5 males and 5 females) at doses of 
250, 500, and 1000 mg/kg bw. The high dose was determined in a preliminary toxicity study. Mice 
from all dose groups were sampled 24 hours after dosing, and mice from top dose and control groups 
were also sampled 48 hours after dosing (Honarvar, 2007a).  
Cyclophosphamide (40 mg/kg bw) was given as the positive control and mice were sampled at 24 
hours. At least 2000 PCEs were scored for each animal for MN. At the highest dose given, 2 males 
and 2 females died, which indicates that higher doses could not have been used. Also in the highest 
dose group the numbers of PCEs were clearly decreased (-35 % at 24 hours) as compared to the mean 
value of PCEs of the vehicle control. This indicates that hex-2(trans)-enal exerts cytotoxic effects in 
the bone marrow at this dose level and demonstrates, in the absence of toxicokinetic measures, that the 
target tissue was exposed. In comparison to the corresponding vehicle controls there was no 
statistically significant increase in the frequency of the detected micronuclei at any preparation 
interval after administration of the test item with any dose level used (Honarvar, 2007a).  
2-Hexenal (unspecified isomer and purity) was evaluated in an in vivo unscheduled DNA synthesis 
assay using oral administration in a GLP study performed according to OECD Guideline 486 (OECD, 
1997c) (Durward, 2009). Male rats were given 200 or 500 mg/kg bw 2-hexenal. The top dose was 
proposed by the sponsor, and a preliminary test by the testing facility demonstrated no deaths at this 
dose. As no other dose levels were used, it is not clear that this was the maximum tolerated dose, and 
perhaps a higher dose could have been used. In one experiment, livers were perfused approximately 16 
hours after dosing and in a second experiment 3 hours after dosing. Following perfusion, hepatocytes 
were processed and areas of nucleus and cytoplasm scored for autoradiographic grains in 150 
cells/animal at each sampling time using automated image analysis. A control group was given only 
corn oil, and positive control groups were administered 2-acetylaminofluorene (16 hours) or N,N’-
dimethylhydrazine (3 hours). Net nuclear grain counts were < 0 at the two harvest times and the 
percentage of cells in repair was low in all animals dosed with 2-hexenal at the 3-hour harvest time. 
The percentage of cells in repair at the 16-hour harvest time was weakly increased with 1.8 ± 1.7 % 
and 2.2 ± 0.6 % cells in repair at 200 and 500 mg/kg respectively vs. 0.4 ± 0.6 % in the concurrent 
control, however, these values are low and within those generally observed. In the absence of an 
increase in the number of net grain per cell, these variations have no meaning in term of genotoxic 
effect. There was therefore no evidence of induction of unscheduled DNA synthesis in animals dosed 
with the test material at either time point.  
2-Dodecenal [FL-no: 05.037] 
2-Dodecenal (purity: 99.4 %) was evaluated in a micronucleus assay in bone marrow PCEs for its 
ability to induce chromosomal damage in mice  in a GLP study performed according to OECD 
Guideline 474 (OECD, 1997b). 2-Dodecenal, dissolved in corn oil as a carrier, was given orally to 
animals (5 males and 5 females) at doses of 500, 1000 and 2000 mg/kg bw. The top dose of 2000 
mg/kg bw is a limit dose for non-toxic substances. Mice from all dose groups were sampled 24 hours 
after dosing, and mice from top dose and control groups were sampled also at 48 hours after dosing. 
Cyclophosphamide (40 mg/kg bw) was given as the positive control and mice were sampled at 24 
hours. At least 2000 PCEs were scored for each animal for MN. No cytotoxic effects were observed at 
any dose, based on the ratio between PCEs and NCEs in each treated sample versus vehicle controls.  
In comparison to the corresponding vehicle controls there was no statistically significant increase in 
the frequency of the detected micronuclei at any preparation interval after administration of the test 
item with any dose level used (Honarvar, 2007b). 
2-Nonenal [FL-no: 05.171] 
2-Nonenal (purity: 96.2 %) was evaluated in a micronucleus assay in bone marrow PCEs for its ability 
to induce chromosomal damage in mice in a GLP study performed according to OECD Guideline 474 
(OECD, 1997b). 2-Nonenal, dissolved in corn oil as a carrier, was given orally to animals (5 males Flavouring Group Evaluation 200 
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and 5 females) at doses of 500, 1000, and 2000 mg/kg bw. The top dose of 2000 mg/kg was estimated 
as suitable by a preliminary study on acute toxicity. Mice from all dose groups were sampled 24 hours 
after dosing, and mice from top dose and control groups were sampled also at 48 hours after dosing. 
Cyclophosphamide (40 mg/kg bw) was given as the positive control and mice were sampled at 24 
hours. At least 2000 PCEs were scored for each animal for MN. The numbers of PCEs were slightly 
decreased, mainly in the top dose group at both sampling times, as compared to the mean value of 
PCEs of the vehicle control (-13 % at 24 and 48 hours sampling times). However, the decrease in % 
PCE was small. In comparison to the corresponding vehicle controls there was no statistically 
significant increase in the frequency of the detected micronuclei  at any preparation interval after 
administration of the test item with any dose level used (Honarvar, 2008).  
For both 2-dodecenal and 2-nonenal tested through micronucleus assays in mouse bone marrow PCE 
(Honarvar, 2007b; Honarvar, 2008) there was no direct confirmation that the bone marrow was 
exposed, as no toxicokinetic measures of the test substance in plasma were made.  
Micronucleus data for hex-2(trans)-enal (Hornavar 2007a), 2-nonenal  (Honarvar, 2008)  and 2-
dodecenal (Honarvar, 2007b) were reported also in a poster abstract (Bhatia et al., 2010). 
The results of in vivo studies are summarised in Table 9. 
3.3.  DNA Adduct and Related Studies 
DNA adduct studies in vitro 
The ability of the α,β-unsaturated aldehydes to bind to isolated nucleosides and nucleotides in vitro 
has been reported (Stout et al., 2008; Eisenbrand et al., 1995; Golzer et al., 1996; Eder et al., 1993). 2-
Hexenal and related α,β-unsaturated aldehydes are capable of forming 1,N
2-cyclic deoxyguanosine 
and 7,8-cyclic guanosine adducts.  
DNA adduct studies in vivo on hex-2(trans)-enal [FL-no: 05.073] 
Using a 
32P-post-labelling method based on nuclease P1 enrichment and TLC separation of the 
labelled adducts
7,  in vivo  studies on hex-2(trans)-enal  report adducts formation. In a first study 
(Schuler et al., 1999) administered hex-2(trans)-enal at a single dose of 500 mg/kg bw by oral route to 
F344 male rats. No adducts were found in the control rats. In treated rats, an adduct (1,N
2-
propanodeoxyguanosine (Hex-PdG)) was detected in the liver. Highest Hex-PdG adduct levels were 
found 2 days after gavage. Four days after gavage, the Hex-PdG adducts level was one third of the 
maximum level but it was even higher than Hex-PdG adducts found after 1 day. No adducts were 
detected 8 hours after gavage. This study demonstrates that after one single high dose of hex-2(trans)-
enal, formation of DNA adducts were induced, that there was a delay before apparition of adducts in 
the liver and that these adducts were repaired only slowly.  
Schuler and Eder (1999) detected Hex-PdG adducts in the forestomach, liver, esophagus and kidneys 
of F344 rats at relatively high single doses, i.e., 200 and 500 mg/kg bw of hex-2(trans)-enal by 
gavage. At 50  mg/kg  bw  Hex-PdG adducts were quantified only in the esophagus. The covalent 
binding index was 0.06, 0.22 and 0.62 at 50, 200 and 500 mg/kg bw respectively (Schuler and Eder, 
1999).   
In the study performed by Stout and colleagues (Stout et al., 2008), using a LC/MS/MS
8 method, no 
adduct formation was reported at 50 mg/kg bw of hex-2(trans)-enal except in forestomach DNA of 
one rat exposed to a single dose and sacrificed 2 days after (Stout et al., 2008). Quantifiable levels of 
Hex-PdG adducts were reported in the forestomach of animals exposed to 100 mg/kg bw/day of hex-
                                                       
7 detection limit 0.03 adducts per 10
6 nucleotides 
8  The limit of quantitation was 0.015 fmol Hex-PdG/μg DNA (200 μg DNA) or 0.006 fmol Hex-PdG/μg DNA (500 μg  
  DNA). Flavouring Group Evaluation 200 
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2(trans)-enal for 1 or 4 weeks (once daily for 5 days per week) and at 200 mg/kg bw of hex-2(trans)-
enal  in single doses. However,  Hex-PdG was not quantifiable in forestomach DNA of rats after 
exposure to 0, 10 or 30 mg/kg for 1 or 4 weeks (Stout et al., 2008). These data are indicative of a dose- 
and time-dependence on DNA adducts formation with hex-2(trans)-enal. Hex-PdG was not 
quantifiable in liver DNA after exposure to 100 mg/kg for 1 or 4 weeks. These findings suggest that 
the genotoxicity of hex-2(trans)-enal was limited to the site of contact (forestomach) and DNA adduct 
formation occurred in the setting of severe tissue damage as demonstrated by histopathological 
observations. At these cytotoxic doses, cell proliferation was noted. The Panel noted that no DNA 
adducts were observed at 30 mg/kg/day and below. 
3.4.  Data on toxicokinetic  
Analogous to other α,β-unsaturated aldehydes, trans-2-hexenal is readily oxidized in vitro to trans-2-
hexenoic acid in the cytosolic fraction of mouse liver cells (Lame and Segall, 1986) and by 
isoenzymes of rat aldehyde dehydrogenase (ALDH)  present in mitochondrial, cytosolic, and 
microsomal fractions (Mitchell and Petersen, 1987). In general, the members of the ALDH 
superfamily demonstrate higher catalytic activity in vitro  for higher molecular weight and more 
lipophilic aldehydes (Nakayasu et al., 1978). 
Prior to absorption, 15% of a 100 mg/kg bw dose of trans-2-nonenal given to rats was oxidized to 
trans-2-nonenoic acid (Grootveld et al., 1998).  
Linear α,β-unsaturated aldehydes are rapidly absorbed, distributed, metabolized and excreted in the 
urine and, to a lesser extent, in the faeces. In in vivo experiments with trans-2-nonenal and trans-2-
pentenal, male Wistar albino rats were administered a bolus dose of 100 mg/kg bw of one of the 
aldehydes by gavage in unheated olive oil. A control group of rats received only the unheated olive 
oil. Urine samples were collected prior to and after administration. 
1H-NMR analysis indicated that 
both trans-2-nonenal and trans-2-pentenal entered systemic circulation from the gastrointestinal tract 
and were metabolized in the fatty acid pathway or were conjugated with glutathione to yield the C-3 
mercapturate conjugate that is excreted mainly in the urine within 24 hours. Trace amounts of trans-2-
nonenal and trans-2-pentenal were detected in the faeces (Grootveld et al., 1998).  
 
PBK/D model 
A recent Physiologically-Based Kinetic/Dynamic (PBK/D) study supports a dose-dependent effect on 
hex-2(trans)-enal detoxification and development of DNA adducts (Kiwamoto et al., 2012, 2013). The 
detoxification of trans-2-hexenal  proceeds  via three pathways: oxidation to 2-hexenoic acid by 
aldehyde dehydrogenase (ALDH), reduction to 2-hexen-1-ol by aldose reductase (AR), conjugation 
with reduced glutathione (GSH) either chemically or catalysed by glutathione S-transferase (GST) 
(Eisenbrand et al., 1995). Kiwamoto et al. (2012) developed a PBK/D model in rats determining in 
vitro kinetic parameters (e.g. Km, Vmax and catalytic efficiency) for each detoxification pathway. 
Performance of the model was evaluated against available in vivo data from literature on rats exposed 
to high doses of trans-2-hexenal (Shuler and Eder, 1999; Stout et al., 2008). In this study, it was shown 
that when hex-2(trans)-enal is incubated with S9-mix fractions of rat liver and rat small intestine, in 
the presence of NAD
+, both fractions predominantly convert the substrate to 2-hexenoic acid which 
does not readily form DNA conjugates and is efficiently eliminated from the urine in the form of 
glucuronic acid conjugates. This model predicts that the conversion of trans-2-hexenal at doses of 0.04 
mg/kg bw (predicted human  dietary exposure) and 200 mg/kg bw (dose at which DNA adduct 
formation in the liver was reported in rats, by Shuler and Eder, 1999) is complete within 3 hours. At 
0.04 mg/kg bw GSH concentration is not affected both in liver and small intestine. At 200 mg/kg bw 
GSH concentration in the small intestine (predicted as the most important detoxification pathway in 
this tissue) dropped rapidly and amounted to only 65% of the initial level after 24 hours; also in the 
liver GSH concentration is depleted, but restored within 24 hours. The model suggests that at low 
doses of trans-2-hexenal, protective levels of GSH are unaffected, while at high doses significant GSH 
depletion occurs. The model predicts that at doses below 80 mg/kg bw  all the three pathways 
contribute to trans-2-hexenal detoxification in the liver. The PBK/D model predicts that hex-2(trans)-Flavouring Group Evaluation 200 
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enal is readily detoxified through glutathione conjugation at 30 mg/kg bw and below. The same model 
was further developed to examine dose-dependent detoxification and DNA adducts  formation in 
humans upon dietary exposure (Kiwamoto et al., 2013). In this study the kinetic parameters were 
derived from literature or calculated through in vitro reactions using human tissue fractions, taking 
into account interindividual differences. The model reveals that rapid in vivo detoxification of hex-
2(trans)-enal at levels of average dietary exposure (0.04 mg/kg bw) makes DNA adduct formation 
negligible (Kiwamoto et al., 2013). Additionally, EFFA estimated a daily exposure of 0.01 mg/kg 
bw/day for hex-2(trans)-enal (EFFA, 2010) which is below the concentrations predicted to induce 
DNA adduct formation. 
The Panel noted that all the metabolic parameters  were obtained from in vitro  studies using rat 
(Kiwamoto et al., 2012) or human (Kiwamoto et al., 2013) liver S9-mix or small intestine S9-mix and 
cofactors or liver mitochondrial fraction to determine the kinetic constants for ALDH-mediated 
oxidation, AR-mediated reduction and GST-catalysed conjugation of GSH with trans-2-hexenal in 
these different tissue fractions. Due to the fact that data were obtained only in vitro, such a model is 
limited. The Panel noted that for these reasons, this model should be considered with cautions. 
3.5.  Discussion of Mutagenicity/Genotoxicity and Related Relevant Data 
In Ames assays, positive results in TA100 and TA104, were reported for several of the substances in 
subgroup 1.1.1, particularly when pre-incubation conditions were used.  Slight  concentration-
dependent increase in revertant colony numbers was observed with hex-2(trans)-enal [FL-no: 05.073] 
and pent-2-enal [FL-no:  05.102]  but not with nona-2(trans),6(cis)-dienal  [FL-no: 05.058]  and  2-
octenal [FL-no: 05.060]. When using a three-fold bacterial cell density, pent-2-enal and hex-2(trans)-
enal were clearly mutagenic with and without metabolic activation; hept-2(trans)-enal induced a weak 
and concentration-dependent mutagenic effect with metabolic activation and it was clearly mutagenic 
without S9-mix. In this assay it was demonstrated that mutagenicity decreased and toxicity increased 
with increasing length of the alkyl chain in β-position (Eder et al., 1992). The authors suggested that 
the dependence of cell toxicity on the increasing β-chain length could be related to the increasing 
lipophilicity.  A double bound in the β-alkyl chain conjugated with that of the acrolein moiety exerted 
a special effect: it increases the mutagenicity significantly (Eder et al., 1992). This has been confirmed 
in recent GLP studies (Sokolowski, 2007a; Sokolowski, 2007b). 
Five alk-2-enals: penta-2-enal, hex-2-enal, hept-2-enals, oct-2-enal and non-2-enal (isomers not 
specified) were tested for mutagenic activity in V79 Chinese  hamster cells. All five alk-2-enals 
induced a concentration-dependent increase of 6-thioguanine (TG) resistant mutants with a statistically 
significant increase at 0.3 mM for penta-2-enal and hex-2-enal, at 0.1 mM for hept-2-enal and oct-2-
enal and at 0.01 mM for non-2-enal. The authors reported that a significant increase in mutation 
frequency is caused by alkyl-2-enal concentrations that caused cytotoxicity. Both mutagenicity and 
cytotoxicity seems directly related to the chain length of the compound. Only hept-2-enal induced a 
statistically significant increase in the frequency of mutations to ouabaine resistance in the same cell 
line (Canonero  et al., 1990).  This study was considered of limited validity because  there is no 
information about the cytotoxicity levels at each concentration tested, the number of tested 
concentrations is limited (2 or 3) and the criteria for their choices not clearly presented. 
Hex-2(trans)-enal [FL-no: 05.073] and trans-2-nonenal [FL-no: 05.072] were positive in an in vitro 
UDS assay performed in primary cultures of rat hepatocytes. Concentrations of both compounds from 
60 to 600 nmol/10
6 cells (equal to 70 nmol/ml to 700 nmol/ml) showed a concentration-dependent 
increase of cells positive for UDS (Griffin and Segall, 1986).  
In the study by Eder et al. (1992), it is shown that in the presence of S9-mix there is a shift in toxicity 
toward higher chemical concentrations, suggesting that S9-mix could lead to partial detoxification. 
Also Marnett et al. (1985) reported that toxicity is an important factor in the detection of enals as 
mutagens. The authors observed positive results only in the presence of glutathione and attributed this 
effect to a partial detoxification that allows survival of bacteria and the growth of revertant colonies. Flavouring Group Evaluation 200 
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In the TA104 strain (which carry one non-sense mutation TAA in the main DNA and not on a plasmid 
like TA102 strain), 2-hexenal [FL-no: 05.189] was mutagenic, but 2-heptenal [FL-no: 05.070], 2-
octenal [FL-no: 05.060] and 2-nonenal [FL-no: 05.171] were not mutagenic. No mutagenic activity 
was observed in the TA102 strain (Marnett et al., 1985).  
Positive evidence of genotoxicity was also reported in other assays (sister chromatid exchange (SCE), 
chromosomal aberrations  (ABS),  micronuclei (MN),  hypoxanthine guanine ribosyl transferase 
(HPRT) mutations, and unscheduled DNA synthesis (UDS)) in mammalian cells, but more particularly 
in cell lines that have low detoxification capacity e.g., Namalva cells and V79 cells (Esterbauer et al., 
1990; Eckl et al., 1993; Canonero et al., 1990; Griffin and Segall, 1986). 
Hex-2(trans)-enal [FL-no: 05.073] (concentrations tested from 5 to 250 µM) and nona-2(trans),6(cis)-
dienal [FL-no: 05.058]  (concentrations tested from 5 to 40 or 50 µM)  were  tested in a human 
lymphoblastoid Namalva cell line and in human lymphocytes for SCE,  ABS  and  MN  induction 
without metabolic activation. Both aldehydes increased the frequency of SCE in the two cell types. 
The treatment with hex-2(trans)-enal induced a statistically significant increase in SCE from 40 µM 
on lymphocytes and 20 µM for Namalva cells.  Nona-2(trans),6(cis)-dienal induced a statistically 
significant increase in  SCE from 20 µM on lymphocytes and 10 µM for Namalva cells.  Nona-
2(trans),6(cis)-dienal was more cytotoxic than hex-2(trans)-enal. In human lymphocytes, neither hex-
2(trans)-enal  nor  nona-2(trans),6(cis)-dienal  induced  statistically  significant increase of structural 
chromosome  aberrations.  On the  contrary, in Namalva cells, both  hex-2(trans)-enal  and  nona-
2(trans),6(cis)-dienal induced structural chromosome aberrations from 100 µM and 5 µM respectively. 
Hex-2(trans)-enal and nona-2(trans),6(cis)-dienal induced aneuploidies in human lymphocytes from 
40µM.  Hex-2(trans)-enal  increased the frequencies of micronuclei both  in lymphocytes and in 
Namalva cells in a concentration-dependent manner. The increase of MN frequency, induced by hex-
2(trans)-enal, was statistically significant in lymphocytes from 50 µM and in Namalva cells from 150 
µM, while for nona-2(trans),6(cis)-dienal a statistically significant increase of MN frequency was 
observed from 20 µM in lymphocytes and from 40 µM in Namalva cells. Using fluorescent in situ 
hybridisation, both lymphocytes and Namalva cells showed significantly enhanced frequencies of 
centromere positive micronuclei for both hex-2(trans)-enal and nona-2(trans),6(cis)-dienal, which is 
coherent with the observation of aneuploidy inductions in the cytogenetic assay. This study shows that 
both  hex-2(trans)-enal  and  nona-2(trans),6(cis)-dienal  gave equivocal results  in  lymphocytes  and 
positive results in Namalva cells, for structural aberrations. While for aneugenicity hex-2(trans)-enal 
and nona-2(trans),6(cis)-dienal were positive in both cell types. The Namalva cells were generally 
more sensitive than lymphocytes. These cells have been found poor or even totally deficient in many 
detoxifying enzymes and they also contain only rather low concentrations of glutathione and  of 
glutathione-related enzymes (Dittberner et al., 1995). 
Using an alkaline elution method, Eisenbrand et al., (1995) demonstrated that Namalva cells were 
significantly more sensitive than primary rat hepatocytes to the induction of DNA strand breaks by 
hexenal. In hepatocytes about 3-5 times higher concentrations of aldehydes were necessary to induce 
significant effects compared to Namalva cells. The authors explained this difference by the better 
enzymatic activity (GSH transferase, aldehyde dehydrogenase) in primary rat hepatocytes compared to 
Namalva cells. In this study, the authors demonstrated that hexenal induced DNA binding in a range of 
doses from 1 to 5 mM (Eisenbrand et al., 1995). 
Dittberner et al. (1997) performed studies on exfoliated cells of human oral mucosa. Seven healthy 
non-smoking volunteers rinsed their mouth 4 times per day for 3 days with 100 ml of hex-2(trans)-
enal [FL-no: 05.073] solution at the concentration of 10 ppm, which represents  a possible 
concentration in food.  Results showed at least a doubling of micronuclei frequency in exfoliated cells 
of human oral mucosa during one of the next four days, then the MN number dropped down to nearly 
the control level. In a second study, seven other volunteers were observed before and after eating 3 - 6 
bananas that contained 35 ppm hex-2(trans)-enal. Six of the seven  volunteers showed at least a 
doubling of the MN frequency during one of the next six days (Dittberner et al., 1997). The Panel 
noted that the results were statistically significant and that the protocol was consistent with standard Flavouring Group Evaluation 200 
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protocols recently developed for biomonitoring studies. Therefore, the results are considered reliable. 
However, the Panel also noted that this kind of studies is not validated for regulatory purposes.  
Primary rat hepatocytes were treated for 3 hours with 0, 0.1, 1.0, 10 and 100 µM of trans-2-nonenal 
[FL-no: 05.072] followed by a 48 hours recovery period. trans-2-Nonenal induced an increase (p < 
0.01) in micronuclei at 10 and 100 µM. At a concentration of 100 µM the mean value of chromosomal 
aberrations was 2.7-fold higher than in the controls, but due to the high standard deviations, these 
increases were not statistically significant (Esterbauer et al., 1990).  
Primary rat hepatocytes were seeded and after 20 hours treated with trans-2-nonenal [FL-no: 05.072] 
at 0, 0.1, 1, 10 or 100 µM for 3 hours. Then the culture medium was replaced by fresh medium added 
with EGF and BrdU (Eckl et al., 1993). 48 hours after the end of the treatment, cells were treated with 
colcemid, and sampled 3 hours later. Slides treated with Hoechst 33258 were used for determination 
of SCE and the other for chromosomal aberration. trans-2-Nonenal induced no significant toxicity at 
the highest concentration tested. trans-2-Nonenal increased neither chromosomal aberrations nor the 
frequency of micronuclei. The Panel noted that in this study, EGF was added to induce cell division, 
but cells were not in division during the period of treatment, this deviation could result in a bias 
compared to recommended protocols. The Panel noted that cells used to determine the induction of 
chromosomal aberrations and micronuclei were pre-treated with BrdU which weakens the 
chromosomes. The  testing for chromosomal aberrations and micronuclei was done after a short 
treatment, followed by a long recovery time which does not appear to be an optimum protocol and is a 
deviation from the OECD Guidelines. Moreover, hepatocytes do not divide all since the mitotic index 
in control cultures ranged from 0.41 to 1.94 %, and no method (such as the addition of cytochalasin B) 
was used to determine the frequency of micronuclei only in cells that divided which reduces the 
sensitivity of this test (Eckl et al., 1993). 
Chung et al. (1999) reported that formation of cyclic propano adducts are common products from 
reactions of enals with DNA bases. Enals derive from lipid peroxidation of cell membrane, but the 
contribution from environmental sources, cannot be excluded. The mutagenicity of enals and the 
mutations observed  in site-specific mutagenesis studies,  using a model for  1,N
2-
propanodeoxyguanosine adducts,  suggest that these adducts are potential promutagenic lesions. The 
authors showed that tissue GSH plays an important role in protecting DNA from cyclic adduction by 
enals.  
Coles and Ketterer (1990) reported that 4-hydroxynon-2-enal is a substrate of different classes of rat 
glutathione transferases that detoxified this compound. But the authors concluded that these enzymes 
do not provide a perfect protection and cytotoxic or genotoxic damage cannot always be avoided. 
Kelson et al. (1997) isolated and characterized a human microsomal fatty aldehyde dehydrogenase, 
which is a distinct human aldehyde dehydrogenase isozyme that acts on a variety of medium- and 
long-chain aliphatic substrates  with a high activity towards saturated and unsaturated aliphatic 
aldehydes ranging from 6 to 24 carbons in length. 
In cell lines poor in detoxification capacity, there is an opportunity for high concentrations (20 to 40 
μM) of α,β-unsaturated aldehydes to either interact directly with DNA or indirectly forming DNA 
adducts due to oxidative stress, leading to single DNA strand breaks but no cross-linking of DNA. The 
depletion of GSH by high concentrations of α,β-unsaturated aldehydes is known to lead to oxidative 
stress and to the release of nucleocytolytic enzymes, causing DNA fragmentation, cellular damage and 
apoptosis (see sections 3.3 and 3.4). Hex-2(trans)-enal, 2-nonenal and 2-dodecenal did not induce MN 
in mice in robust GLP studies (Honarvar, 2007a, 2007b, 2008). However, only for hex-2(trans)-enal 
exposure  of the target tissue was demonstrated.  In addition, hex-2(trans)-enal did not induce 
unscheduled DNA synthesis in rat hepatocytes at doses up to 500 mg/kg bw in a GLP study (Durward, 
2009).  Flavouring Group Evaluation 200 
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However, this type of assays does not address the potential clastogenicity in the gastrointestinal tract. 
While such studies have not been conducted, due to structure similarity it seems to be possible that 
lifetime gavage administration of high concentrations of hex-2(trans)-enal [FL-no: 05.073] to rats 
might result in carcinogenicity in the forestomach or esophagus, similar to that observed for 2,4-
hexadienal (subgroup 1.1.4 of FGE.19, EFSA CEF Panel, 2014). It is also likely that the ulcerative and 
necrotising lesions and consequent regenerative cell proliferation in the forestomach produced under 
these unique conditions would be associated with increased DNA adducts, as was observed in the 
hexenal DNA adduct study (Stout et al., 2008). However, production of exocyclic guanine adducts 
following glutathione depletion may be involved, but the evidence from the 2-hexenal and 2,4-
hexadienal studies suggests that these events are associated with significant tissue damage (ulceration, 
inflammation and hyperplasia) related to high bolus dosing by gavage. The inflammation and tissue 
damage could affect the normal biochemical processes involved in the metabolism of α,β-unsaturated 
aldehydes and their detoxification. The reduced metabolic activity could increase the probability of a 
direct reaction between aldehydes and DNA nucleotides.  
A recent PBK/D model shows that 2-hexenal is rapidly detoxified predominantly by conjugation with 
glutathione (GSH) by glutathione S-transferases, and that the rapid detoxification of 2-hexenal reduces 
the risk arising from 2-hexenal exposure through the diet. Thus, dietary exposure to doses that do not 
deplete glutathione, and therefore do not lead either to tissue damage or DNA adducts would not be 
expected to pose a mutagenic or carcinogenic hazard (Kiwamoto et al., 2012, 2013). However, the 
Panel considered that PBK/D studies are not sufficient due to the lack of validation.   
Hex-2(trans)-enal induced weak gene mutations in bacteria. When tested in the Muta™Mouse assay 
up to the maximum tolerated dose of 350 mg/kg bw/day, hex-2(trans)-enal was not mutagenic in the 
tissues of the duodenum, presumably the first point of contact for the test material upon transit from 
the glandular stomach. These results are also supported by no indication of mutagenic activity in the 
liver, primary point of metabolism.  
Hex-2(trans)-enal tested for chromosomal aberrations in mammalian cell lines showed positive 
results, but resulted  negative in the in vivo  micronucleus test performed in  peripheral blood 
reticulocytes (Beevers, 2013) and in bone marrow (Honavar, 2007a).   
In summary, the available data indicate that at high concentrations of hex-2(trans)-enal no gene 
mutations were induced in the liver and duodenum of transgenic mice after a daily treatment for 28 
days up to 350 mg/kg bw/day (Beevers, 2013). DNA adducts were detected in the forestomach, liver, 
esophagus and kidneys of rats treated with hex-2(trans)-enal by gavage at relatively high single doses, 
i.e., 200 and 500 mg/kg bw and at 50 mg/kg in the esophagus. DNA adducts were not quantifiable in 
forestomach DNA of rats after exposure to 10 or 30 mg/kg bw for 1 or 4 weeks (Schuler and Eder, 
1999). However, in the same experimental condition, DNA adducts were detected locally (duodenum 
and esophagus) and systemically (kidney and liver) at doses lower than the dose that proved  no 
induction of gene mutation. The Panel noted that overall the available experimental data from animals 
and humans, while not showing an induction of gene mutations, do not allow to assess the potential 
clastogenic activity of hex-2(trans)-enal at the first site of contact and in the liver, where high levels of 
DNA adducts were observed.  
CONCLUSION 
The new data submitted are related only to one representative substance of subgroup 1.1.1, hex-
2(trans)-enal [FL-no: 05.073]. 
For hex-2(trans)-enal [FL-no: 05.073] gene mutations were observed in vitro  in TA100,  and 
chromosomal aberrations were observed in vitro likewise. In addition, a biomonitoring study in human 
buccal cells showed a statistically significant increase in the frequency of micronuclei at 
concentrations that might be relevant for the use of hex-2(trans)-enal as flavouring substances. The 
new submitted study performed on a Muta
TMMouse model does not cover these endpoints adequately. Flavouring Group Evaluation 200 
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The Panel noted that overall the available experimental data from animals and humans, while not 
showing an induction of gene mutations, do not allow to assess the potential clastogenic activity of 
hex-2(trans)-enal at the first site of contact and in the liver where higher levels of DNA adducts were 
observed than in other tissues investigated. Therefore, the new data provided by the Industry do not 
rule out the genotoxicity concern for the substances of subgroup 1.1.1. 
For both 2-dodecenal and 2-nonenal tested through micronucleus assays in mouse bone marrow PCE 
(Honarvar, 2007b; Honarvar, 2008) there was no direct confirmation that the bone marrow was 
exposed, as no toxicokinetic measures of the test substance in plasma were made. 
Under these conditions, the Panel confirms, the need for an  in vivo  Comet assay  performed in 
duodenum and liver for hex-2(trans)-enal [FL-no: 05.073]. For the two other representative substances 
of subgroup 1.1.1 (nona-2(trans),6(cis)-dienal [FL-no: 05.058] and oct-2-enal [FL-no: 05.060]),  a 
combined in vivo Comet assay and micronucleus assay would be required. For the latter, evidence of 
target tissue exposure should be provided.  
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Table 3:   Specification Summary of the Substances in the Present Group Evaluation 
FL-no 
JECFA-no 
EU Register name  Structural formula  FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 
(a) 
Solubility in ethanol 
(b) 
Boiling point, °C 
(c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
(d) 
Spec.gravity 
(e) 
02.020 
1354 
Hex-2-en-1-ol 
OH  
2562 
69 
2305-21-7 
Liquid 
C6H12O 
100.16 
Very slightly soluble 
Soluble 
158-160 
 
IR 
95 % 
1.437-1.442 
0.836-0.841 
02.049 
1184 
Nona-2,6-dien-1-ol  OH  2780 
589 
7786-44-9 
Liquid 
C9H16O 
140.23 
Insoluble 
Soluble 
196 
 
IR NMR MS 
95 % 
1.463-1.465 
0.860-0.880 
02.050 
1793 
Pent-2-en-1-ol 
OH   
665 
20273-24-9 
Liquid 
C5H10O 
86.13 
 
Freely soluble 
141 
 
MS 
95 % 
1.427-1.433 
0.844-0.850 
02.090 
1365 
Non-2(trans)-en-1-ol  OH  3379 
10292 
31502-14-4 
Liquid 
C9H18O 
142.23 
Insoluble 
Soluble 
105 (16 hPa) 
 
IR 
95 % 
1.444-1.448 
0.835-0.845 
02.112 
1369 
Non-2(cis)-en-1-ol 
OH
 
3720 
10292 
41453-56-9 
Liquid 
C9H18O 
142.23 
Slightly soluble 
Soluble 
96 (13 hPa) 
 
NMR 
96 % 
1.447-1.453 
0.841-0.847 
02.137 
1794 
Dec-2-en-1-ol  OH   
11750 
22104-80-9 
Liquid 
C10H20O 
156.27 
 
Freely soluble 
117 (19 hPa) 
 
MS 
95 % 
1.446-1.452 
0.842-0.848 
02.156 
1374 
Hex-2(cis)-en-1-ol 
OH
 
3924 
69 
928-94-9 
Liquid 
C6H12O 
100.16 
Insoluble 
Soluble 
65 (0.7 hPa) 
 
NMR 
92 % 
1.437-1.445 
0.845-0.853 
02.157 
 
Hex-2(trans)-en-1-ol 
OH 
2562 
69 
2305-21-7 
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Table 3:   Specification Summary of the Substances in the Present Group Evaluation 
FL-no 
JECFA-no 
EU Register name  Structural formula  FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 
(a) 
Solubility in ethanol 
(b) 
Boiling point, °C 
(c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
(d) 
Spec.gravity 
(e) 
02.192 
 
Oct-2-en-1-ol 
OH  
3887 
11804 
22104-78-5 
Liquid 
C8H16O 
128 
Insoluble 
Soluble 
88 (hPa) 
 
MS 
96 % 
1.4371-1.4571 
0.8384-0.8584 
02.210 
1384 
Undec-2-en-1-ol 
OH
  4068 
 
37617-03-1 
Liquid 
C11H22O 
170.30 
Insoluble 
Soluble 
100-102 (3 hPa) 
 
IR 
95 % 
1.447-1.453 
0.838-0.848 
02.231 
 
tr-2, cis-6-Nonadien-1-ol 
OH 
2780 
589 
28069-72-9 
Liquid 
C9H16O 
140.23 
Insoluble 
Soluble 
196 
 
MS 
95 % 
1.463-1.465 
0.860-0.880 
05.037 
1350 
2-Dodecenal  O  2402 
124 
4826-62-4 
Liquid 
C12H22O 
182.31 
Practically insoluble 
or insoluble 
Freely soluble 
272 
 
IR 
93 % 
1.452-1.458 
0.839-0.849 
05.058 
1186 
Nona-2(trans),6(cis)-
dienal 
O
 
3377 
659 
557-48-2 
Liquid 
C9H14O 
138.21 
Insoluble 
Soluble 
94 
 
IR 
92 % 
1.470-1.475 
0.850-0.870 
05.060 
1363 
Oct-2-enal 
O  
3215 
663 
2363-89-5 
Liquid 
C8H14O 
126.20 
Slightly soluble 
Soluble 
84-86 (25 hPa) 
 
IR 
92 % 
1.449-1.455 
0.835-0.845 
05.070 
1360 
2-Heptenal  O
 
3165 
730 
2463-63-0 
Liquid 
C7 H12 O 
112.17 
Practically insoluble 
or insoluble 
Freely soluble 
166 
 
IR MS 
97 % 
1.428-1.434 
0857-0.863 
05.072 
1362 
trans-2-Nonenal  O  3213 
733 
18829-56-6 
Liquid 
C9 H16 O 
140.22 
Practically insoluble 
or insoluble 
Freely soluble 
90 (1,2T) 1.333 
 
IR MS 
92 % 
1.454-1.460 
0.855-0.865 Flavouring Group Evaluation 200 
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Table 3:   Specification Summary of the Substances in the Present Group Evaluation 
FL-no 
JECFA-no 
EU Register name  Structural formula  FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 
(a) 
Solubility in ethanol 
(b) 
Boiling point, °C 
(c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
(d) 
Spec.gravity 
(e) 
05.073 
1353 
Hex-2(trans)-enal 
O 
2560 
748 
6728-26-3 
Liquid 
C6 H10 O 
98.14 
Very slightly soluble 
Freely soluble 
47 (1.7T) 2.266 
 
NMR MS 
92 % 
1.443-1.449 
0.841-0.848 
05.076 
1349 
Dec-2-enal  O  2366 
2009 
3913-71-1 
Liquid 
C10H18O 
154.25 
Insoluble 
Soluble 
229 
 
IR 
92 % 
1.452-1.458 
0.836-0.846 
05.078 
1359 
Tridec-2-enal  O 3082 
2011 
7774-82-5 
Liquid 
C13H24O 
196.33 
Insoluble 
Soluble 
115-118 (13hPa) 
 
IR 
92 % 
1.455-1.461 
0.842-0.862 
05.102 
1364 
Pent-2-enal  O  3218 
10375 
764-39-6 
Liquid 
C5H8O 
84.11 
Insoluble 
Soluble 
124 
 
NMR 
98 % 
1.440-1.447 (21°) 
0.850-0.856 (21°) 
05.109 
1366 
2-Undecenal 
O
  3423 
11827 
2463-77-6 
Liquid 
C11H20O 
168.27 
Insoluble 
Soluble 
115 (13 hPa) 
 
NMR 
98 % 
1.452-1.459 
0.837-0.847 
05.111 
1182 
Octa-2(trans),6(trans)-
dienal 
O  
3466 
10371 
56767-18-1 
Liquid 
C8H12O 
124.19 
Insoluble 
Soluble 
97-99 (5 hPa) 
 
IR NMR 
96 % 
1.469-1.475 
0.835-0.841 
05.114 
1208 
4-Methylpent-2-enal 
O
 
3510 
10364 
5362-56-1 
Liquid 
C6H10O 
98.14 
Slightly soluble 
Soluble 
126-130 
 
IR NMR 
97 % 
1.435-1.445 
0.858-0.866 
05.120 
1197 
Dodeca-2,6-dienal  O  3637 
 
21662-13-5 
Liquid 
C12H20O 
180.28 
Insoluble 
Soluble 
130 (7 hPa) 
 
NMR 
97.5 % 
1.425-1.431 
0.987-0.993 Flavouring Group Evaluation 200 
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Table 3:   Specification Summary of the Substances in the Present Group Evaluation 
FL-no 
JECFA-no 
EU Register name  Structural formula  FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 
(a) 
Solubility in ethanol 
(b) 
Boiling point, °C 
(c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
(d) 
Spec.gravity 
(e) 
05.144 
 
Dodec-2(trans)-enal  O  2402 
 
20407-84-5 
 
 
 
 
 
 
 
 
 
 
 
05.150 
1360 
Hept-2(trans)-enal 
O
  3165 
730 
18829-55-5 
Liquid 
C7H12O 
112.17 
Insoluble 
Soluble 
165-167 
 
IR 
97 % 
1.428-1.434 
0.857-0.863 
05.171 
1362 
Non-2-enal  O
(E)-isomer shown  
3213 
733 
2463-53-8 
Liquid 
C9H16O 
140.22 
Insoluble 
Soluble 
88-90 (16 hPa) 
 
IR 
92 % 
1.454-1.460 
0.855-0.865 
05.172 
1187 
Nona-2(trans),6(trans)-
dienal 
O  3766 
 
17587-33-6 
Liquid 
C9H14O 
138.21 
Insoluble 
Soluble 
88 (14 hPa) 
 
NMR 
97 % 
1.439-1.445 
0.856-0.864 
05.179 
1803 
Tetradec-2-enal  O  4209 
 
51534-36-2 
Solid 
C14H26O 
210.36 
 
Freely soluble 
88 (0.3 hPa) 
35 
MS 
95 % 
1.455-1.562 
n.a. 
05.184 
 
Undec-2(trans)-enal 
O
  3423 
11827 
53448-07-0 
Liquid 
C11H20O 
168.27 
Insoluble 
Soluble 
115 (1.3 hPa) 
 
MS 
98 % 
1.452-1.459 
0.837-0.847 
05.189 
 
2-Hexenal 
O   
748 
505-57-7 
 
 
 
 
 
 
 
 
 
 
 
05.190 
 
trans-2-Octenal 
O  3215 
 
2548-87-0 
Liquid 
C8H14O 
126.2 
Soluble 
Soluble 
96 (2.5 hPa) 
 
MS 
92 % 
1.449-1.455 
0.835-0.845 Flavouring Group Evaluation 200 
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Table 3:   Specification Summary of the Substances in the Present Group Evaluation 
FL-no 
JECFA-no 
EU Register name  Structural formula  FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 
(a) 
Solubility in ethanol 
(b) 
Boiling point, °C 
(c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
(d) 
Spec.gravity 
(e) 
05.191 
 
trans-2-Decenal  O  2366 
 
3913-81-3 
 
 
 
 
 
 
 
 
 
 
 
05.195 
 
trans-2-Tridecenal  O  3082 
 
7069-41-2 
Liquid 
C13H24O 
196.33 
Insoluble 
Soluble 
117 (1.3 hPa) 
 
MS 
92 % 
1.455-1.462 
0.842-0.862 
06.025 
946 
1,1-Diethoxynona-2,6-
diene 
O
O
 
3378 
660 
67674-36-6 
Liquid 
C13H24O2 
212.33 
Insoluble 
Miscible 
125 (5 hPa) 
 
IR 
90 % 
1.441-1.448 
0.860-0.868 
06.031 
1383 
1,1-Diethoxyhex-2-ene  O
O  
4047 
2135 
54306-00-2 
Liquid 
C10H20O2 
172.27 
Practically insoluble 
or insoluble 
Freely soluble 
66 (8T) 10.6657 
 
MS 
95 % 
1.418-1.426 
0.843-0.849 
06.072 
1728 
1,1-Dimethoxyhex-
2(trans)-ene 
O
O
 
 
 
18318-83-7 
Liquid 
C8H16O2 
144.21 
 
Freely soluble 
158 
 
NMR 
95 % 
1.420-1.424 
0.867-0.871 
09.054 
2 
Allyl butyrate 
O
O
 
2021 
280 
2051-78-7 
Liquid 
C7H12O2   
128.17 
Insoluble 
Soluble 
44-45 (20 hPa) 
 
IR 
98 % 
1.412 - 1.418 
0.897 - 0.902 
09.097 
4 
Allyl heptanoate 
O
O
 
2031 
369 
142-19-8 
Liquid 
C10H18O2    
170.25 
 
Freely soluble 
210 
 
IR 
97 % 
1.426 - 1.430 
0.880 - 0.885 
09.109 
6 
Allyl nonanoate 
O
O  
2036 
390 
7493-72-3 
Liquid 
C12H22O2    
198.31 
Insoluble 
Soluble 
241-242 
 
IR 
96.5 % 
1.430 - 1.436 
0.872 - 0.880 Flavouring Group Evaluation 200 
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Table 3:   Specification Summary of the Substances in the Present Group Evaluation 
FL-no 
JECFA-no 
EU Register name  Structural formula  FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 
(a) 
Solubility in ethanol 
(b) 
Boiling point, °C 
(c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
(d) 
Spec.gravity 
(e) 
09.119 
5 
Allyl octanoate 
O
O  
2037 
400 
4230-97-1 
Liquid 
C11H20O2   
184.28 
Insoluble 
Soluble 
222 
 
IR 
97 % 
1.432 - 1.434 
0.872 - 0.880 
09.146 
9 
Allyl undec-10-enoate 
O
O
 
2044 
441 
7493-76-7 
Liquid 
C14H24O2    
224.34 
Insoluble 
Soluble 
180 (39 hPa) 
 
IR 
98 % 
1.448 at 30° 
0.8802 at 30° 
09.233 
1 
Allyl propionate 
O
O  
2040 
2094 
2408-20-0 
Liquid 
C6H12O2    
114.15 
 
 
122-123 
 
IR 
99 % 
1.4105 
0.914 at 20° 
09.244 
3 
Allyl hexanoate 
O
O  
2032 
2181 
123-68-2 
Liquid 
C9H16O2 
156.22 
Insoluble 
1 ml in 6 ml 70% 
ethanol 
185 
 
IR 
98 % 
1.422 - 1.426 
0.884 - 0.890 
09.247 
 
Allyl crotonate 
O
O  
4072 
2222 
20474-93-5 
Liquid 
C7H10O2 
126.15 
 
Freely soluble 
146 
 
MS 
95 % 
 
0.932-0.937 
09.276 
1367 
Oct-2-enyl acetate 
O
O
 
3516 
11906 
3913-80-2 
 
 
170.25 
 
 
 
 
 
 
 
 
09.277 
1368 
Oct-2(trans)-enyl butyrate 
O
O  
3517 
11907 
84642-60-4 
Liquid 
C12H22O2 
198.30 
Insoluble 
Soluble 
112-113 (10hPa) 
 
IR NMR MS 
96 % 
1.433-1.439 
0.890-0.896 
09.303 
1799 
Hept-2-enyl isovalerate 
O
O
(E)-isomer shown  
4126 
10664 
 
Liquid 
C12H22O2 
198.30 
 
Freely soluble 
263 
 
NMR 
95 % 
 
0868-0.873 Flavouring Group Evaluation 200 
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Table 3:   Specification Summary of the Substances in the Present Group Evaluation 
FL-no 
JECFA-no 
EU Register name  Structural formula  FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 
(a) 
Solubility in ethanol 
(b) 
Boiling point, °C 
(c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
(d) 
Spec.gravity 
(e) 
09.312 
8 
Allyl hexa-2,4-dienoate  O
O  
2041 
2182 
7493-75-6 
Liquid 
C9H12O2    
152.19  
 
Soluble 
67 
 
IR 
99 % 
1.506 
0.945 -0.947 
09.385 
1798 
Hept-2-enyl acetate 
O
O
(E)-isomer shown  
4125 
10661 
16939-73-4 
Liquid 
C9H16O2 
156.22 
 
Freely soluble 
193 
 
MS 
95 % 
1.428-1.434 
0.889-0.895 
09.394 
1355 
Hex-2(trans)-enyl acetate 
O
O
 
2564 
643 
2497-18-9 
Liquid 
C8H14O2 
142.20 
Very slightly soluble 
Soluble 
165-166 
 
IR 
90 % 
1.424-1.430 
0.890-0.897 
09.395 
1378 
Hex-2(trans)-enyl 
propionate 
O
O  
3932 
11830 
53398-80-4 
Liquid 
C9H16O2 
156.23 
Insoluble 
Soluble 
91 (26 hPa) 
 
NMR 
95 % 
1.426-1.433 
0.885-0.895 
09.396 
1375 
Hex-2-enyl butyrate 
O
O  
3926 
 
53398-83-7 
 
 
 
 
 
 
 
 
 
 
 
09.397 
1376 
Hex-2-enyl formate 
O O   3927 
11858 
53398-78-0 
 
 
 
 
 
 
 
 
 
 
 
09.398 
1381 
Hex-2-enyl hexanoate 
O
O  
3983 
 
53398-86-0 
 
 
 
 
 
 
 
 
 
 
 
09.399 
1377 
Hex-2-enyl isovalerate 
O
O
 
3930 
 
35154-45-1 
Liquid 
C11H20O2 
184.28 
Insoluble 
Soluble 
105 (26 hPa) 
 
NMR 
96 % 
1.425-1.435 
0.875-0.885 Flavouring Group Evaluation 200 
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Table 3:   Specification Summary of the Substances in the Present Group Evaluation 
FL-no 
JECFA-no 
EU Register name  Structural formula  FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 
(a) 
Solubility in ethanol 
(b) 
Boiling point, °C 
(c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
(d) 
Spec.gravity 
(e) 
09.400 
 
Hex-2-enyl phenylacetate  
O
O  
 
 
68133-78-8 
Solid 
C14H18O2 
218.29 
Practically insoluble 
or insoluble 
Freely soluble 
336 
37 
NMR 
95 % 
n.a. 
n.a. 
09.410 
11 
Allyl 2-ethylbutyrate 
O
O
 
2029 
281 
7493-69-8 
Liquid 
C9H16O2   
156.23 
Insoluble 
Soluble 
165-167 
 
IR 
99 % 
1.422 - 1.427 
0.882 - 0.887 
09.411 
14 
Allyl cyclohexanebutyrate 
O
O
 
2024 
283 
7493-65-4 
Liquid 
C13H22O2    
210.31 
Insoluble 
Soluble 
104 (1 hPa) 
 
NMR 
98 % 
1.4608 at 20.5° 
0.943-0.949 
09.469 
15 
Allyl cyclohexanevalerate 
O
O
 
2027 
474 
7493-68-7 
Liquid 
C14H24O2    
224.34 
insoluble 
Soluble 
119 (1 hPa) 
 
IR 
98 % 
1.4605 at 22° 
0.942-0.947 
09.482 
12 
Allyl cyclohexaneacetate 
O
O
 
2023 
2070 
4728-82-9 
Liquid 
C11H18O2   
182.26 
 
Soluble 
60 (1 hPa) 
 
NMR 
96 % 
1.455 - 1.499 
0.945 - 0.965 
09.489 
7 
Allyl isovalerate 
O
O
 
2045 
2098 
2835-39-4 
Liquid 
C8H14O2    
142.20 
Insoluble 
Freely soluble 
155 
 
IR 
98 % 
1.413-1.418 
0.879 - 0.884 
09.492 
16 
Allyl 
cyclohexanehexanoate 
O
O
 
2025 
2180 
7493-66-5 
Liquid 
C14H28O2    
238.37 
Insoluble 
Soluble 
128 (2 hPa) 
 
NMR 
98 % 
1.462 
0.941-0.947 
09.493 
10 
Allyl 2-methylcrotonate 
O
O
 
2043 
2183 
7493-71-2 
Liquid 
C8H12O2   
140.18 
Slightly soluble 
 
153 
 
IR 
98 % 
1.451 - 1.454 
0.939 - 0.943 Flavouring Group Evaluation 200 
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Table 3:   Specification Summary of the Substances in the Present Group Evaluation 
FL-no 
JECFA-no 
EU Register name  Structural formula  FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 
(a) 
Solubility in ethanol 
(b) 
Boiling point, °C 
(c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
(d) 
Spec.gravity 
(e) 
09.498 
13 
Allyl 
cyclohexanepropionate 
O
O
 
2026 
2223 
2705-87-5 
Liquid 
C12H20O2    
196.29 
Insoluble 
1 ml in 4 ml 80% 
ethanol 
91 (1 hPa) 
 
IR 
98 % 
1.457 - 1.462 
0.945 - 0.950 
09.678 
1795 
Pent-2-enyl hexanoate 
O
O
(E)-isomer shown  
4191 
 
74298-89-8 
Liquid 
C11H20O2 
184.28 
 
Freely soluble 
241 
 
MS 
95 % 
1.425-1.435 
0.885-0.895 
09.701 
18 
Allyl phenoxyacetate 
O
O
O  
2038 
228 
7493-74-5 
Liquid 
C11H12O3    
192.22 
 
 
100-102 (1 hPa) 
 
IR 
97.5 % 
1.512 - 1.519 
1.00 - 1.11 
09.719 
20 
Allyl anthranilate 
NH2
O
O
 
2020 
254 
7493-63-2 
Liquid 
C10H11O2N  
177.21 
Almost insoluble 
 
105 (3 hPa) 
 
IR 
98 % 
1.569-1.577 
1.12 
09.741 
19 
Allyl cinnamate 
O
O
 
2022 
334 
1866-31-5 
Liquid 
C12H12O2 
188.22 
Insoluble 
Miscible 
286 
 
IR 
97 % 
1.562-1.569 
1.050-1.056 
09.790 
17 
Allyl phenylacetate 
O
O
 
2039 
2162 
1797-74-6 
Liquid 
C11H12O2    
176.22 
 
 
89-93 (4 hPa) 
 
IR 
99 % 
1.5122 at 13.5° 
1.033-1.041 
09.841 
1796 
2-Hexenyl octanoate 
O
O
(E)-isomer shown  
4135 
 
85554-72-9 
Liquid 
C14H26O2 
226.36 
 
Freely soluble 
309 
 
MS 
95 % 
 
 Flavouring Group Evaluation 200 
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Table 3:   Specification Summary of the Substances in the Present Group Evaluation 
FL-no 
JECFA-no 
EU Register name  Structural formula  FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 
(a) 
Solubility in ethanol 
(b) 
Boiling point, °C 
(c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
(d) 
Spec.gravity 
(e) 
09.866 
 
Allyl valerate 
O
O
 
4074 
 
 
Liquid 
C8H14O2 
142.20 
 
Freely soluble 
58 (16 hPa) 
 
MS 
95 % 
 
0.999-1.005 
09.947 
1188 
(E,Z)-2,6-Nonadienyl 
acetate 
O
O
 
3952 
 
68555-65-7 
Liquid 
C11H18O2 
182.26 
Sparingly soluble 
Soluble 
231 
 
IR NMR MS 
95 % 
1.448-1.458 
0.905-0.907 
09.948 
 
(2E)-2-Nonenyl acetate 
O
O
 
4552 
 
30418-89-4 
Liquid 
C11H20O2 
184.79 
Sparingly soluble 
Very soluble 
228 
 
IR NMR MS 
98 % 
1.4325-1.4425 
0.874-0.894 
13.004 
21 
Allyl 2-furoate 
O
O
O
 
2030 
360 
4208-49-5 
Liquid 
C8H8O3    
152.15 
 
 
206-209 
 
IR 
98 % 
1.4945 
1.181 (23°) 
(a): Solubility in water, if not otherwise stated. 
(b): Solubility in 95 % ethanol, if not otherwise stated. 
(c): At 1013.25 hPa, if not otherwise stated. 
(d): At 20°C, if not otherwise stated. 
(e): At 25°C, if not otherwise stated. Flavouring Group Evaluation 200 
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SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE  
Table 4:   Summary of Safety Evaluation of the JECFA Substances in the Present Group 
FL-no 
JECFA-no 
EU Register name  Structural formula  EU MSDI 
(a)  
US MSDI 
(µg/capita/day) 
Class 
(b) 
Evaluation procedure 
path 
(c) 
JECFA Outcome 
on the named 
compound  
(d) or (e) 
EFSA conclusion on the named 
compound  
02.020 
1354 
Hex-2-en-1-ol  OH  340 
291 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required 
02.049 
1184 
Nona-2,6-dien-1-ol  OH  1.9 
1 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required 
02.090 
1365 
Non-2(trans)-en-1-ol  OH  0.12 
0.03 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required 
02.112 
1369 
Non-2(cis)-en-1-ol 
OH
 
 
0.065 
2 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required 
05.037 
1350 
2-Dodecenal  O  0.12 
2 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required 
05.058 
1186 
Nona-2(trans),6(cis)-
dienal 
O
 
 
6.1 
24 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required 
05.060 
1363 
Oct-2-enal 
O  
 
3.3 
0.9 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required 
05.070 
1360 
2-Heptenal  O
 
 
5.4 
 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required 
05.072 
1362 
trans-2-Nonenal  O 
 
0.12 
 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required 
05.076 
1349 
Dec-2-enal  O 
 
2.6 
6 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required 
05.078 
1359 
Tridec-2-enal  O 
 
0.49 
0.7 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required 
05.102 
1364 
Pent-2-enal 
O 
0.67 
0.1 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required Flavouring Group Evaluation 200 
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Table 4:   Summary of Safety Evaluation of the JECFA Substances in the Present Group 
FL-no 
JECFA-no 
EU Register name  Structural formula  EU MSDI 
(a)  
US MSDI 
(µg/capita/day) 
Class 
(b) 
Evaluation procedure 
path 
(c) 
JECFA Outcome 
on the named 
compound  
(d) or (e) 
EFSA conclusion on the named 
compound  
05.109 
1366 
2-Undecenal 
O
 
 
0.33 
0.4 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required 
05.111 
1182 
Octa-2(trans),6(trans)-
dienal 
O  
 
0.12 
0.007 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required 
05.114 
1208 
4-Methylpent-2-enal 
O
 
 
0.24 
0.2 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required  
05.120 
1197 
Dodeca-2,6-dienal  O 
 
0.44 
0.009 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required  
05.150 
1360 
Hept-2(trans)-enal 
O
 
 
5.1 
30 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required  
05.171 
1362 
Non-2-enal  O
(E)-isomer shown  
 
1.7 
0.4 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required  
05.172 
1187 
Nona-2(trans),6(trans)-
dienal 
O 
 
ND 
0.007 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required 
06.025 
946 
1,1-Diethoxynona-2,6-
diene 
O
O
 
 
0.037 
0.01 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required 
06.031 
1383 
1,1-Diethoxyhex-2-ene  O
O  
 
0.24 
 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required 
09.276 
1367 
Oct-2-enyl acetate 
O
O
 
 
0.18 
0.7 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required 
09.277 
1368 
Oct-2(trans)-enyl butyrate 
O
O  
 
0.26 
0.7 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required 
09.394 
1355 
Hex-2(trans)-enyl acetate 
O
O
 
 
170 
56 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required  Flavouring Group Evaluation 200 
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Table 4:   Summary of Safety Evaluation of the JECFA Substances in the Present Group 
FL-no 
JECFA-no 
EU Register name  Structural formula  EU MSDI 
(a)  
US MSDI 
(µg/capita/day) 
Class 
(b) 
Evaluation procedure 
path 
(c) 
JECFA Outcome 
on the named 
compound  
(d) or (e) 
EFSA conclusion on the named 
compound  
09.395 
1378 
Hex-2(trans)-enyl 
propionate 
O
O  
 
ND 
4 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required  
09.396 
1375 
Hex-2-enyl butyrate 
O
O  
 
ND 
4 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required 
09.397 
1376 
Hex-2-enyl formate  O O  
 
ND 
7 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required 
09.398 
1381 
Hex-2-enyl hexanoate 
O
O  
 
ND 
0.09 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required 
09.399 
1377 
Hex-2-enyl isovalerate 
O
O
 
 
ND 
4 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required 
09.947 
1188 
(E,Z)-2,6-Nonadienyl 
acetate  O
O
 
 
1.2 
 
Class I 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required 
02.156 
1374 
Hex-2(cis)-en-1-ol 
OH
 
 
ND 
10 
Class I 
No evaluation 
  Evaluated in FGE.200, additional 
genotoxicity data required 
02.157 
 
Hex-2(trans)-en-1-ol  OH 
 
340 
291 
Class I 
No evaluation 
   
02.210 
1384 
Undec-2-en-1-ol 
OH 
 
ND 
1 
Class I 
No evaluation 
  Evaluated in FGE.200, additional 
genotoxicity data required  
05.189 
 
2-Hexenal 
O 
 
675 
409 
Class I 
No evaluation 
   
09.948 
 
(2E)-2-Nonenyl acetate 
O
O
 
 
1.2 
 
Class I 
No evaluation 
   
02.137 
1794 
Dec-2-en-1-ol  OH  0.12 
 
Class I 
No evaluation 
  Evaluated in FGE.200, additional 
genotoxicity data required 
05.179 
1803 
Tetradec-2-enal  O  0.061 
 
Class I 
No evaluation 
  Evaluated in FGE.200, additional 
genotoxicity data required  Flavouring Group Evaluation 200 
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Table 4:   Summary of Safety Evaluation of the JECFA Substances in the Present Group 
FL-no 
JECFA-no 
EU Register name  Structural formula  EU MSDI 
(a)  
US MSDI 
(µg/capita/day) 
Class 
(b) 
Evaluation procedure 
path 
(c) 
JECFA Outcome 
on the named 
compound  
(d) or (e) 
EFSA conclusion on the named 
compound  
09.303 
1799 
Hept-2-enyl isovalerate 
O
O
(E)-isomer shown  
0.0012 
 
Class I 
No evaluation 
  Evaluated in FGE.200, additional 
genotoxicity data required 
09.385 
1798 
Hept-2-enyl acetate 
O
O
(E)-isomer shown  
0.0061 
 
Class I 
No evaluation 
  Evaluated in FGE.200, additional 
genotoxicity data required 
09.400 
 
Hex-2-enyl phenylacetate 
O
O
 
0.012 
 
Class I 
No evaluation 
   
09.678 
1795 
Pent-2-enyl hexanoate 
O
O
(E)-isomer shown  
 
0.4 
 
Class I 
No evaluation 
  Evaluated in FGE.200, additional 
genotoxicity data required  
09.841 
1796 
2-Hexenyl octanoate 
O
O
(E)-isomer shown  
 
0.012 
 
Class I 
No evaluation 
  Evaluated in FGE.200, additional 
genotoxicity data required 
09.244 
3 
Allyl hexanoate  O
O  
2600 
820 
Class II 
B3: Intake above threshold 
Data must be 
available e 
Evaluated in FGE.200, additional 
genotoxicity data required. 
Evaluated by JECFA before 2000 
09.054 
2 
Allyl butyrate 
O
O
 
11 
<0.01 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required. 
Evaluated by JECFA before 2000   
09.097 
4 
Allyl heptanoate 
O
O
 
130 
28 
Class II 
A3: Intake above threshold, 
A4: Endogenous 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required. 
Evaluated by JECFA before 2000 
09.109 
6 
Allyl nonanoate 
O
O  
<0.01 
0.01 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required. 
Evaluated by JECFA before 2000 Flavouring Group Evaluation 200 
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Table 4:   Summary of Safety Evaluation of the JECFA Substances in the Present Group 
FL-no 
JECFA-no 
EU Register name  Structural formula  EU MSDI 
(a)  
US MSDI 
(µg/capita/day) 
Class 
(b) 
Evaluation procedure 
path 
(c) 
JECFA Outcome 
on the named 
compound  
(d) or (e) 
EFSA conclusion on the named 
compound  
09.119 
5 
Allyl octanoate  O
O  
45 
1.3 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required. 
Evaluated by JECFA before 2000 
09.146 
9 
Allyl undec-10-enoate 
O
O
 
<0.01 
<0.01 
Class II 
A3: Intake above threshold, 
A4: Endogenous 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required. 
Evaluated by JECFA before 2000 
09.233 
1 
Allyl propionate  O
O  
7.9 
<0.01 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required. 
Evaluated by JECFA before 2000 
09.312 
8 
Allyl hexa-2,4-dienoate 
O
O  
<0.01 
<0.01 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data 
required 
Evaluated in FGE.200, additional 
genotoxicity data required. 
Evaluated by JECFA before 2000 
09.410 
11 
Allyl 2-ethylbutyrate 
O
O
 
0.26 
0.02 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required. 
Evaluated by JECFA before 2000 
09.411 
14 
Allyl cyclohexanebutyrate 
O
O
 
0.14 
<0.01 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required. 
Evaluated by JECFA before 2000 
09.469 
15 
Allyl cyclohexanevalerate 
O
O
 
0.14 
<0.01 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required. 
Evaluated by JECFA before 2000 
09.482 
12 
Allyl cyclohexaneacetate  O
O
 
<0.01 
<0.01 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required. 
Evaluated by JECFA before 2000 
09.489 
7 
Allyl isovalerate 
O
O
 
0.38 
0.19 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required. 
Evaluated by JECFA before 2000 Flavouring Group Evaluation 200 
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Table 4:   Summary of Safety Evaluation of the JECFA Substances in the Present Group 
FL-no 
JECFA-no 
EU Register name  Structural formula  EU MSDI 
(a)  
US MSDI 
(µg/capita/day) 
Class 
(b) 
Evaluation procedure 
path 
(c) 
JECFA Outcome 
on the named 
compound  
(d) or (e) 
EFSA conclusion on the named 
compound  
09.492 
16 
Allyl 
cyclohexanehexanoate 
O
O
 
0.36 
<0.01 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required. 
Evaluated by JECFA before 2000  
09.493 
10 
Allyl 2-methylcrotonate 
O
O
 
1.3 
<0.01 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required. 
Evaluated by JECFA before 2000 
09.498 
13 
Allyl 
cyclohexanepropionate  O
O
 
220 
110 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required. 
Evaluated by JECFA before 2000 
09.741 
19 
Allyl cinnamate 
O
O
 
 
4.6 
0.28 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required. 
Evaluated by JECFA before 2000 
09.790 
17 
Allyl phenylacetate 
O
O
 
 
6.5 
<0.01 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required. 
Evaluated by JECFA before 2000 
09.701 
18 
Allyl phenoxyacetate 
O
O
O  
 
30 
2.5 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required. 
Evaluated by JECFA before 2000 
09.719 
20 
Allyl anthranilate 
NH2
O
O
 
 
0.12 
0.09 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required. 
Evaluated by JECFA before 2000 Flavouring Group Evaluation 200 
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Table 4:   Summary of Safety Evaluation of the JECFA Substances in the Present Group 
FL-no 
JECFA-no 
EU Register name  Structural formula  EU MSDI 
(a)  
US MSDI 
(µg/capita/day) 
Class 
(b) 
Evaluation procedure 
path 
(c) 
JECFA Outcome 
on the named 
compound  
(d) or (e) 
EFSA conclusion on the named 
compound  
13.004 
21 
Allyl 2-furoate 
O
O
O
 
 
0.12 
<0.01 
Class III 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data 
required 
Evaluated in FGE.200, additional 
genotoxicity data required. 
Accepted by JECFA at step B5 
05.073 
1353 
Hex-2(trans)-enal 
O  
670 
 
 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required 
06.072 
1728 
1,1-Dimethoxyhex-
2(trans)-ene 
O
O
 
 
0.12 
 
 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required  
02.050 
1793 
Pent-2-en-1-ol  OH  0.57 
 
 
A3: Intake below threshold 
(d)  Evaluated in FGE.200, additional 
genotoxicity data required 
02.192 
 
Oct-2-en-1-ol 
OH 
1800 
 
 
No evaluation 
Not evaluated by 
the JECFA 
Evaluated in FGE.200, additional 
genotoxicity data required 
02.231 
 
tr-2,cis-6-Nonadien-1-ol 
OH 
 
1.0 
 
 
No evaluation 
Not evaluated by 
the JECFA 
Evaluated in FGE.200, additional 
genotoxicity data required 
05.144 
 
Dodec-2(trans)-enal  O   
 
 
No evaluation 
Not evaluated by 
the JECFA 
Evaluated in FGE.200, additional 
genotoxicity data required 
05.184 
 
Undec-2(trans)-enal 
O
 
 
0.34 
 
 
No evaluation 
Not evaluated by 
the JECFA 
Evaluated in FGE.200, additional 
genotoxicity data required 
05.190 
 
trans-2-Octenal 
O 
 
0.89 
 
 
No evaluation 
Not evaluated by 
the JECFA 
Evaluated in FGE.200, additional 
genotoxicity data required 
05.191 
 
trans-2-Decenal  O 
 
 
 
 
No evaluation 
Not evaluated by 
the JECFA 
Evaluated in FGE.200, additional 
genotoxicity data required 
05.195 
 
trans-2-Tridecenal  O 
 
0.11 
 
 
No evaluation 
Not evaluated by 
the JECFA 
Evaluated in FGE.200, additional 
genotoxicity data required 
09.247 
 
Allyl crotonate 
O
O  
0.41 
 
 
No evaluation 
Not evaluated by 
the JECFA 
Evaluated in FGE.200, additional 
genotoxicity data required Flavouring Group Evaluation 200 
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Table 4:   Summary of Safety Evaluation of the JECFA Substances in the Present Group 
FL-no 
JECFA-no 
EU Register name  Structural formula  EU MSDI 
(a)  
US MSDI 
(µg/capita/day) 
Class 
(b) 
Evaluation procedure 
path 
(c) 
JECFA Outcome 
on the named 
compound  
(d) or (e) 
EFSA conclusion on the named 
compound  
09.866 
 
Allyl valerate 
O
O
 
0.012 
 
 
No evaluation 
Not evaluated by 
the JECFA 
Evaluated in FGE.200, additional 
genotoxicity data required 
(a):  EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365) = µg/capita/day. 
(b):  Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
(c):  Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
(d):  No safety concern based on intake calculated by the MSDI approach of the named compound. 
(e):  Data must be available on the substance or closely related substances to perform a safety evaluation. 
ND: not determined. Flavouring Group Evaluation 200 
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(Q)SAR PREDICTIONS ON MUTAGENICITY FOR ALDEHYDES FROM SUBGROUP 1.1.1 
Table 5:   QSAR Predictions on Mutagenicity for 25 Aldehydes from Subgroup 1.1.1 
FL-no 
JECFA-no 
EU Register name  Structural formula 
(a)  ISS Local Model 
Ames Test TA100 
(b) 
 
MultiCASE 
Ames test 
(c) 
 
MultiCASE 
Mouse 
lymphoma test 
(d) 
MultiCASE 
Chromosomal 
aberration test in 
CHO 
(e) 
MultiCASE 
Chromosomal 
aberration test in 
CHL 
(f) 
05.176 
 
Prop-2-enal  O
  POS  POS  OD  NEG  OD 
05.102 
1364 
Pent-2-enal 
O  POS  POS  OD  NEG  NEG 
05.114 
1208 
4-Methylpent-2-enal 
O
 
POS  NEG  OD  NEG  NEG 
05.189 
1353 
2-Hexenal 
O  POS  POS  OD  NEG  NEG 
05.073 
 
Hex-2(trans)-enal 
O  POS  POS  OD  NEG  NEG 
Not in 
Register 
Hex-2(cis)-en-1-al  O
  POS  POS  OD  NEG  NEG 
05.150 
1360 
Hept-2(trans)-enal  O
  POS  POS  OD  NEG  NEG 
05.070 
 
2-Heptenal  O
  POS  POS  OD  NEG  NEG 
05.060 
1363 
Oct-2-enal 
O  POS  EQU  OD  NEG  NEG 
05.190 
 
trans-2-Octenal 
O  POS  EQU  OD  NEG  NEG 
05.171 
1362 
Non-2-enal 
O  POS  EQU  OD  NEG  NEG 
05.072 
 
trans-2-Nonenal 
O  POS  EQU  OD  NEG  NEG 
Not in 
Register 
Non-2(cis)-en-1-al 
O  POS  EQU  OD  NEG  NEG Flavouring Group Evaluation 200 
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Table 5:   QSAR Predictions on Mutagenicity for 25 Aldehydes from Subgroup 1.1.1 
FL-no 
JECFA-no 
EU Register name  Structural formula 
(a)  ISS Local Model 
Ames Test TA100 
(b) 
 
MultiCASE 
Ames test 
(c) 
 
MultiCASE 
Mouse 
lymphoma test 
(d) 
MultiCASE 
Chromosomal 
aberration test in 
CHO 
(e) 
MultiCASE 
Chromosomal 
aberration test in 
CHL 
(f) 
05.076 
1349 
Dec-2-enal 
O  POS  EQU  OD  NEG  NEG 
05.191 
 
trans-2-Decenal 
O  POS  EQU  OD  NEG  NEG 
05.109 
1366 
2-Undecenal  O
  POS  EQU  OD  NEG  NEG 
05.144 
 
Dodec-2(trans)-enal 
O  POS  EQU  OD  NEG  NEG 
05.037 
1350 
2-Dodecenal 
O  POS  EQU  OD  NEG  NEG 
05.078 
1359 
Tridec-2-enal 
O  POS  EQU  OD  NEG  NEG 
05.179 
 
Tetradec-2-enal 
O  POS  EQU  OD  NEG  NEG 
05.111 
1182 
Octa-2(trans),6(trans)-
dienal 
O  NEG  EQU  OD  NEG  NEG 
Not in 
Register 
Nona-2,6-dien-1-al 
O  NEG  NEG  OD  NEG  NEG 
05.058 
1186 
Nona-2(trans),6(cis)-
dienal 
O
 
NEG  NEG  OD  NEG  NEG 
05.172 
1187 
Nona-2(trans),6(trans)-
dienal 
O  NEG  NEG  OD  NEG  NEG 
05.120 
1197 
Dodeca-2,6-dienal 
O  NEG  EQU  OD  NEG  NEG 
(a): Structure subgroup.  
(b): Local model on aldehydes and ketones, Ames TA100. (NEG: Negative; POS: Positive; OD: out of domain). 
(c): MultiCase Ames test (OD: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal). 
(d): MultiCase Mouse Lymphona test (OD: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal). 
(e): MultiCase Chromosomal aberration in CHO (OD: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal). 
(f): MultiCase Chromosomal aberration in CHL (OD: Out of domain; POS: Positive; NEG: Negative; EQU: Equivocal). Flavouring Group Evaluation 200 
 
EFSA Journal 2014;12(6):3709  41 
 
GENOTOXICITY DATA 
Table 6:   Genotoxicity Data (in vitro) Considered by the Panel 
Register name 
[FL-no] 
End-point  Test system  Concentration  Results  Reference  Remarks* 
Nona-2(trans),6(cis)-dienal 
[05.058] 
Reverse mutation  S. typhimurium 
TA100 
0.01 – 0.1 µl/plate 
(8.6 – 86 µg/plate)
a [4,1] 
Negative  Eder et al., 1992  Valid. 
Standard bacterial density was used. 
30-min pre-incubation. 
a Calculated using specific gravity = 0.850–
0.870g/ml (Food and Chemicals Codex, 1996). 
Reverse mutation  S. typhimurium 
TA100 
0.005 – 0.15 µl/plate 
(4.3 – 129 µg/plate)
a [4,1] 
0.005 – 0.20 µl/plate 
(4.3 – 172 µg/plate)
a [4,2] 
Negative  Eder et al., 1992  Valid. 
 Three-fold bacterial cell density was used. 
90-min pre-incubation. 
a Calculated using specific gravity = 0.850–
0.870g/ml (Food and Chemicals Codex, 1996). 
SOS chromotest  E. coli PQ37 
and PQ243 
5 – 80 nmol 
(0.69  – 11 µg/l) 
Negative  Eder et al., 1992  Valid. 
Sister chromatid 
exchange 
Human 
lymphoblastoid 
Namalva cell 
line 
0 – 40 µM 
(0 – 5.5 µg/ml) [1] 
Positive  Dittberner et al., 1995  Valid. 
 
Sister chromatid 
exchange 
Primary human 
blood 
lymphocytes 
0 – 50 µM 
(0 – 6.9 µg/ml) [1] 
Positive  Dittberner et al., 1995  Valid. 
 
Structural 
chromosomal 
aberration test 
Human 
lymphoblastoid 
Namalva cell 
line 
0 – 40 µM 
(0 – 5.5 µg/ml) [1] 
Positive  Dittberner et al., 1995  Valid. 
 
Structural 
chromosomal 
aberration test 
Primary human 
blood 
lymphocytes 
0 – 40 µM 
(0 – 5.5 µg/ml) [1] 
Equivocal  Dittberner et al., 1995  Valid. 
 
Numerical 
chromosomal 
aberration test 
Primary human 
blood 
lymphocytes 
0 - 40 µM 
(0 - 5.5 µg/ml) [1] 
Positive  Dittberner et al., 1995   Valid. 
 
Micronucleus  Primary human  0 – 50 µM  Positive  Dittberner et al., 1995  Valid. Flavouring Group Evaluation 200 
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Register name 
[FL-no] 
End-point  Test system  Concentration  Results  Reference  Remarks* 
formation  blood 
lymphocytes 
(0 – 6.9 µg/ml) [1]   
Micronucleus 
formation 
Human 
lymphoblastoid 
Namalva cell 
line 
0 – 50 µM 
(0 – 6.9 µg/ml) [1] 
Positive  Dittberner et al., 1995  Valid. 
 
Hex-2(trans)-enal  
[05.073] 
Reverse Mutation  S. typhimurium 
TA98, TA100, 
and TA104 
Not reported [4,5]  Positive  Kato et al., 1989  Validity cannot be evaluated. Abstract only. 
 According to the authors, 2-hexenal was 
“suspected to be positive” (Kato et al., 1989); 
however, no further details were provided. 
Liquid pre-incubation was used. 
Reverse Mutation  S. typhimurium 
TA100 
0.05 - 0.35 μl/plate  [4,1] 
0.15 – 0.5 μl/plate  [4,2] 
Negative
 
 
Eder et al., 1992  Valid. 
Standard bacterial cell density was used. 
30-min pre-incubation. 
Reverse Mutation  S. typhimurium 
TA100 
0.01 - 0.15 μl/plate  [4,1] 
0.1 – 0.4 μl/plate [4,2]  
Positive
 
 
Eder et al., 1992  Valid. 
 Three-fold bacterial cell density was used. 
90-min pre-incubation. 
SOS Chromotest  E. coli PQ37 
and PQ243 
70 - 435 nmol (6.9 - 42.7 
μg)
a 
Negative  Eder et al., 1992  Valid. 
Cytotoxicity was observed at the highest dose 
tested. 
 a Calculated using the molecular weight of 2-
hexenal = 98.14. 
Mutation  E. coli 
WP2uvrA/pKM
101 
Not reported [5]  Positive  Kato et al., 1989  Validity cannot be evaluated.Abstract only.
  
According to the authors, 2-hexenal was 
“suspected to be positive” (Kato et al., 1989); 
however, no further details were provided. 
Liquid pre-incubation was used. 
Micronucleus 
Induction 
Human blood 
lymphocytes 
5 - 250 μM 
(0.5 - 24.5 μg/ml) [1] 
Positive  Dittberner et al., 1995  Valid. 
 
Micronucleus 
Induction 
Lymphoblastoid 
Namalva cells 
5 - 250 μM 
(0.5 - 24.5 μg/ml) [1] 
Positive  Dittberner et al., 1995  Valid. 
 
Chromosomal 
Aberration 
Human blood 
lymphocytes 
5 - 250 μM 
(0.5 - 24.5 μg/ml) [1] 
Negative  Dittberner et al., 1995  Valid. 
 
Chromosomal 
Aberration 
Lymphoblastoid 
Namalva cells 
5 - 150 μM 
(0.5 - 14.7 μg/ml) [1] 
Positive  Dittberner et al., 1995  Valid. 
  
Sister Chromatid  Human blood  5 - 250 μM  Positive  Dittberner et al., 1995  Valid. Flavouring Group Evaluation 200 
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Register name 
[FL-no] 
End-point  Test system  Concentration  Results  Reference  Remarks* 
Exchange  lymphocytes  (0.5 - 24.5 μg/ml)
 [1]   
Sister Chromatid 
Exchange 
Lymphoblastoid 
Namalva cells 
5 - 200 μM 
(0.5 - 19.6 μg/ml) [1] 
Positive  Dittberner et al., 1995  Valid. 
 
DNA Repair  Rat hepatocytes  60 - 600 nmol/10
6 cells 
(5.9 - 58.9 μmol)
a 
Positive  Griffin and Segall, 1986  Valid 
Study design complies with OECD Guideline 
482. UDS clearly increased at two highest 
concentrations with only moderate toxicity. 
 a Calculated using the molecular weight of 2-
hexenal = 98.14. 
Pent-2-enal  
[05.102] 
Reverse mutation   S. typhimurium 
TA100  
0.075 – 0.5 µl/plate [4,1] 
0.075 – 0.75 µl/plate  
[4,2] 
Positive  Eder et al., 1992  Valid. 
Standard bacterial cell density was used. 
30-min pre-incubation. 
Reverse mutation   S. typhimurium 
TA100  
0.01 – 0.25 µl/plate [4,1] 
0.1 – 0.4 µl/plate  [4,2] 
Positive  Eder et al., 1992  Valid. 
Three-fold bacterial cell density was used.  
90-min pre-incubation. 
SOS chromotest  E. coli PQ37 
and PQ243 
60 – 435 nmol 
(5.0 – 36.7 µg)
a 
Negative  Eder et al., 1992  Valid.  
Cytotoxicity was observed at the highest dose 
tested. 
a Calculated using the molecular weight of 2-
pentenal = 84.12. 
Mutation 
induction 
TG resistance 
Chinese hamster 
V79 cells 
0.03, 0.10 or 0.30 mM 
(2.5, 8.4 or 25.2 µg/ml)
a 
[1] 
Positive  
 
Canonero et al., 1990  Limited validity.  
No data on cytotoxicity were provided, 2 or 3 
doses were tested and unclear criteria to choose 
dose range. A dose-dependent increase in the 
number of 6-thioguanine mutants was observed. 
a Calculated using the molecular weight of 2-
pentenal = 84.12. 
Mutation 
induction 
Ouavaine 
resistance 
Chinese hamster 
V79 cells 
0.03, 0.10 or 0.30 mM 
(2.5, 8.4 or 25.2 µg/ml)
a 
[1] 
Negative  
 
Canonero et al., 1990  Limited validity.  
No data on cytotoxicity were provided, 2 or 3 
doses were tested and unclear criteria to choose 
dose range 
a Calculated using the molecular weight of 2-
pentenal = 84.12. 
DNA single 
strand break 
Mouse 
leukaemia cells 
L1210 
400, 600 or 800 µmol 
(33.648, 50.472 or 67.296 
µg)
a 
Positive  Eder et al., 1993  Limited validity. 
Results were not reported in detail. However, 
the authors stated that pentenal was slightly 
positive at doses at which cytotoxicity was just Flavouring Group Evaluation 200 
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Register name 
[FL-no] 
End-point  Test system  Concentration  Results  Reference  Remarks* 
starting. Cytotoxicity was observed at the 
highest dose tested. 
a Calculated using the molecular weight of 2-
pentenal = 84.12. 
2-Heptenal [05.070]  Reverse mutation  S. typhimurium 
TA104 
Up to 0.9 µmol/plate
a 
(101 µg/plate)
b [4,1] 
Negative  Marnett et al., 1985  Validity cannot be evaluated. 
 
Results were not reported in detail. Liquid pre-
incubation procedure was used. 
a Maximum non-toxic dose. 
b Calculated using the molecular weight of 2-
heptenal = 112.17. 
Reverse mutation  S. typhimurium 
TA104 
Up to 4.4 µmol/plate
a 
(493.5 µg/plate)
b[4,1] 
 
Negative  Marnett et al., 1985  Validity cannot be evaluated. 
 
Results were not reported in detail. Liquid pre-
incubation procedure was used. Addition of 
glutathione at 10 mM. 
a Maximum non-toxic dose. 
b Calculated using the molecular weight of 2-
heptenal = 112.17. 
Reverse mutation  S. typhimurium 
TA100 
 
0.01 – 0.15 µl/plate  [4,1] 
0.075 – 0.3 µl/plate  [4,2] 
Negative  Eder et al., 1992  Valid. 
Standard bacterial cell density was used. 30-
min pre-incubation. Dose-dependent increases 
in mutation frequency were noted; however, 
these increases were never two-fold higher than 
the spontaneous mutation frequency. 
Reverse mutation  S. typhimurium 
TA100 
 
0.005 – 0.1 µl/plate [4,1] 
0.025 – 0.3 µl/plate [4,2] 
Negative  Eder et al., 1992  Valid. 
Three-fold bacterial cell density assay was 
used. 90-min pre-incubation. 
Dose-dependent increases in mutation 
frequency were noted; however, these increases 
were never two-fold higher than the 
spontaneous mutation frequency. 
SOS chromotest  E. coli PQ37 
and PQ243 
35 – 270 nmol 
(3.9 – 30.3 µg)
a 
Negative  Eder et al., 1992  Valid.   
Cytotoxicity was observed at the highest dose 
tested. 
a Calculated using the molecular weight of 2-
heptenal = 112.17. 
Mutation 
induction 
TG resistance 
Chinese hamster 
V79 cells 
0.01, 0.03 or 0.10 mM 
(1.1, 3.4 or 11.2 µg/ml)
a 
[1] 
Positive  Canonero et al., 1990  Limited validity. 
 No data on cytotoxicity were provided, 2 or 3 
doses were tested and unclear criteria to choose Flavouring Group Evaluation 200 
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Register name 
[FL-no] 
End-point  Test system  Concentration  Results  Reference  Remarks* 
  dose range.  Dose-dependent increases in the 
number of 6-thioguanine and ouabain mutants 
were observed. 
a Calculated using the molecular weight of 2-
heptenal = 112.17. 
Mutation 
induction 
Ouabaine 
resistance 
Chinese hamster 
V79 cells 
0.01, 0.03 or 0.10 mM 
(1.1, 3.4 or 11.2 µg/ml)
a 
[1] 
 
Negative  Canonero et al., 1990  Limited validity.  
No data on cytotoxicity were provided, 2 or 3 
doses were tested and unclear criteria to choose 
dose range. 
a Calculated using the molecular weight of 2-
heptenal = 112.17. 
DNA single 
strand break 
Mouse 
leukaemia 
L1210 cells 
200, 400 or 500 µmol 
(22.434, 44.868 or 56.085 
µg)
a 
Positive  Eder et al., 1993  Limited validity. 
Results were not reported in detail. However, 
the authors stated that heptenal was positive at 
non-toxic doses. 
a Calculated using the molecular weight of 2-
heptenal = 112.17. 
trans-2-Nonenal [05.072]  Micronucleus 
formation  
Rat hepatocytes   0.1, 1, 10 or 100 µM 
(0.01, 0.1, 1.4 or 14.0 
µg/ml) 
Positive 
  Esterbauer et al., 1990  Limited validity. 
Difficult to interpret since the result was 
expressed as number of cells with micronuclei 
per mitotic index 1.00 minus control. However, 
the result is considered valid. The authors of 
this study were the same as these from Eckl et 
al. (1993). 
  Micronucleus 
formation  
Rat hepatocytes   0.1, 10 or 100 µM 
(0.01, 1.4 or 14.0 µg/ml) 
Equivocal  Eckl et al., 1993  Limited validity. 
Cells were not under cell division at the 
treatment time. 
  Chromosomal 
aberration  
Rat hepatocytes   0.1, 1, 10 or 100 µM 
(0.01, 0.1, 1.4 or 14.0 
µg/ml) 
Negative   Esterbauer et al., 1990  Validity cannot fully be evaluated since types 
of chromosomal aberrations were not reported. 
  Chromosomal 
aberration  
Rat hepatocytes   0.1, 10 or 100 µM 
(0.01, 1.4 or 14.0 µg/ml) 
Negative   Eckl et al., 1993  Validity cannot fully be evaluated since types 
of chromosomal aberrations were not reported. 
Cells were not under cell divisions at the 
treatment time. 
  Sister chromatid 
exchange  
Rat hepatocytes   0.1, 10 or 100 µM 
(0.01, 1.4 or 14.0 µg/ml) 
Equivocal  Eckl et al., 1993  Limited validity. 
Cells were not under cell division at the 
treatment time. Flavouring Group Evaluation 200 
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Register name 
[FL-no] 
End-point  Test system  Concentration  Results  Reference  Remarks* 
  DNA repair   Rat hepatocytes   60 – 600 nmol/10
6 cells 
(8.4 – 84.1 µg/plate) 
 
Positive   Griffin and Segall, 1986  Valid. Study design complies with OECD 
Guideline 482. UDS clearly increased at four 
highest concentrations. Maximum at the mid 
concentration with only moderate toxicity. At 
increased levels of toxicity also decline in the 
net grain counts. 
Non-2-enal [05.171] 
 
  
Reverse mutation   S. typhimurium 
TA104  
Up to 0.007 µmol/plate 
a 
(1.0 µg/plate) [4,1] 
Negative
  Marnett et al., 1985  Validity cannot be evaluated. 
 
Results were not reported in detail. 
Liquid pre-incubation procedure was used. 
a Maximum non-toxic dose. 
Mutation 
induction  
TG resistance 
Chinese hamster 
V79 cells  
0.003 or 0.01 mM 
(0.4 or 1.4 µg/ml) [1] 
Positive 
 
Canonero et al., 1990  Limited validity.  
No data on cytotoxicity were provided, 2 or 3 
doses were tested and unclear criteria to choose 
dose range. A dose-dependent increase in the 
number of 6-thioguanine mutants was observed. 
Mutation 
induction  
Ouabaine 
resistance 
Chinese hamster 
V79 cells  
0.003 or 0.01 mM 
(0.4 or 1.4 µg/ml) [1] 
Negative 
 
Canonero et al., 1990  Limited validity.  
No data on cytotoxicity were provided, 2 or 3 
doses were tested and unclear criteria to choose 
dose range 
 
2-Hexenal [05.189]  Reverse mutation  S. typhimurium 
TA98, TA100, 
TA1535 and 
TA1537 
3 µmol/plate 
(294.4 µg/plate)
a [5] 
Negative 
 
Florin et al., 1980  Insufficient validity. Not in accordance with 
OECD Guideline 471 (inadequate study design, 
spot test, only one concentration tested). 
Isomeric composition of test substance not 
given. 
a Calculated using the molecular weight of 2-
hexenal = 98.14. 
Reverse Mutation  S. typhimurium 
TA104 
Up to 2 μmol/plate
a 
(196.3 μg/plate)
b [4,1] 
Positive  Marnett et al., 1985  Validity cannot be evaluated.  
Results were not reported in detail. Isomeric 
composition of test substance not given. Liquid 
pre-incubation procedure was used. 
a Maximum non-toxic dose. 
b Calculated using the molecular weight of 2-
hexenal = 98.14. 
Reverse Mutation  S. typhimurium 
TA104 
 
5 μmol/plate
a 
(> 490.7 μg/plate)
b [4,1] 
Positive  Marnett et al., 1985  Validity cannot be evaluated. 
 
Results were not reported in detail.  
Isomeric composition of test substance not 
given. Liquid pre-incubation procedure was 
used. Addition of 10 mM glutathione. Flavouring Group Evaluation 200 
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Register name 
[FL-no] 
End-point  Test system  Concentration  Results  Reference  Remarks* 
a Maximum non-toxic dose. 
b Calculated using the molecular weight of 2-
hexenal = 98.14. 
Reverse Mutation  S. typhimurium 
TA102 
 
Up to 2 μmol/plate
a 
(196.3 μg/plate)
b [4,1] 
Negative  Marnett et al., 1985  Validity cannot be evaluated. 
 
Results were not reported in detail. Isomeric 
composition of test substance not given. Liquid 
pre-incubation procedure was used. 
a Maximum non-toxic dose. 
b Calculated using the molecular weight of 2-
hexenal = 98.14. 
Mutation 
induction 
TG resistance 
Chinese hamster 
V79 cells 
0.03, 0.10 or 0.30 mM 
(2.9, 9.8 or 29.4 µg/ml)
a 
[1] 
Positive
 
 
Canonero et al., 1990  Limited validity.  
No data on cytotoxicity were provided, 2 or 3 
doses were tested and unclear criteria to choose 
dose range. A dose-dependent increase in the 
number of 6-thioguanine mutants was observed.
 
a Calculated using the molecular weight of 2-
hexenal = 98.14. 
Mutation 
induction 
Ouabaine 
resistance 
Chinese hamster 
V79 cells 
0.03, 0.10 or 0.30 mM 
(2.9, 9.8 or 29.4 µg/ml)
a 
[1] 
Negative
 
 
Canonero et al., 1990  Limited validity.  
No data on cytotoxicity were provided, 2 or 3 
doses were tested and unclear criteria to choose 
dose range. 
a Calculated using the molecular weight of 2-
hexenal = 98.14. 
DNA Single 
Strand Break 
L1210 mouse 
leukemia cells 
 
100, 250 or 500 μmol 
(9.814, 24.535 or 
49.070μg)
a 
 
Positive  Eder et al., 1993  Limited validity. 
Results were not reported in detail. However, 
the authors stated that hexenal was positive at 
non-toxic doses. Cytotoxicity was observed at 
the highest dose tested. Isomeric composition 
of test substance not given. 
a Calculated using the molecular weight of 2-
hexenal = 98.14. 
2-Octenal [05.060]  Bacterial Reverse 
Mutation 
S. typhimurium 
TA104 
Up to 0.8 µmol/plate
a 
(101.0 μg/plate)
b [4,1] 
Negative  Marnett et al., 1985  Validity cannot be evaluated.  
Results were not reported in detail. Liquid pre-
incubation procedure was used.  
a Maximum non-toxic dose. 
b Calculated using the molecular weight of 2-
octenal = 126.20. Flavouring Group Evaluation 200 
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Register name 
[FL-no] 
End-point  Test system  Concentration  Results  Reference  Remarks* 
    S. typhimurium 
TA104 
Up to 4 µmol/plate
a 
(504.8 μg/plate)
b [4,1] 
Negative  Marnett et al., 1985  Validity cannot be evaluated.  
Results were not reported in detail. Liquid pre-
incubation procedure was used.  
Addition of 10 mM glutathione. 
a Maximum non-toxic dose. 
b Calculated using the molecular weight of 2-
octenal = 126.20. 
  Mutation 
Induction 
TG resistance 
Ouabain 
resistance 
Chinese hamster 
V79 cells 
0.01, 0.03 or 0.10 mM 
(1.3, 3.8 or 12.6 μg/ml) 
[1] 
Positive 
(TG 
resistance:  
HPRT 
mutation) 
 
Negative 
(Ouabain 
resistance) 
Canonero et al., 1990  Limited validity.  
No data on cytotoxicity were provided, 2 or 3 
doses were tested and unclear criteria to choose 
dose range.  
The test was performed only without metabolic 
activation. No significant increase relative to 
controls was observed in the number of ouabain 
mutants. 
  DNA Single 
Strand Breaks 
L1210 mouse 
leukemia cells 
250, 350 µmol 
(44 mg/plate) 
Positive  Eder et al., 1993  Limited validity. 
Results were not reported in detail. However, 
the authors stated that hexenal was positive at 
350 µmol 
[1] Without S9 metabolic activation. 
[2] With S9 metabolic activation. 
[3] Plate incorporation method. 
[4] Pre-incubation method. 
[5] With and without S9 metabolic activation. 
 
*Validity of genotoxicity studies: 
Valid 
Limited validity (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and / or limited documentation) 
Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards inappropriate / not validated test system) 
Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided, text not in a Community language)  
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Table 7:   Genotoxicity Data (in vivo) Considered by the Panel 
Register name 
[FL-no] 
End-point  Test system  Concentration  Results  Reference  Remarks 
Hex-2(trans)-enal  
[05.073] 
Micronucleus 
Induction 
Human buccal mucosa cells  10 mg/kg  Positive  Dittberner et al., 1997  Valid. 
Statistically significant increases in 
micronuclei were observed on days 
4, 5, 6 and 7 post-administration. 
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Table 8:   Additional Genotoxicity Data (in vitro) Considered by the Panel in FGE.200 
Register name  
[FL-no]  
Test System   Test Object   Concentration    Result   Reference   Comments 
Hex-2(trans)-enal  
 [05.073]  
Reverse Mutation   S. typhimurium TA98, TA100, 
TA102, TA1535, TA1537 
3 - 5000 μg/plate [3,5] 
 
 
Negative   Sokolowski, 2007a  A moderate concentration –
dependent increase in 
revertant colony number was 
observed in strain TA100, in 
the absence of S9-mix. Study 
design complies with OECD 
Guidelines 471  
  S. typhimurium TA100  1 - 2500 μg/plate [4,5]  Positive[4,1]   
   S. typhimurium TA100   25- 200 μg/plate [4,5]  Positive[4,1]   
  Reverse Mutation   S. typhimurium TA98, TA100, 
TA102, TA1535, TA1537  
3- 5000 μg/plate [3,5] 
 
Negative 
 
Bhatia et al., 2010  Same test as Sokolowski, 
2007a 
    S. typhimurium TA100  1 - 2500 μg/plate [4,5]  Positive [4,1]     
    S. typhimurium TA100   25 -200 μg/plate [4,1]   Positive [4,1]     
2-Dodecenal [05.037]   Reverse Mutation   S. typhimurium TA98, TA100, 
TA102, TA1535, and TA1537  
3 - 5000 μg/plate [3,5]  Negative
   Sokolowski, 2007b   Concentrations up to 5000 
μg/plate were used in a pre-
experiment test. Toxic 
effects as a reduction in the 
number of revertants were 
observed at the higher 
concentrations.  
      0.1– 100 μg/plate [3,1] 
1 - 1000 μg/plate [3,2] 
Negative   
      0.3 - 1000 μg/plate [4,5]  Negative   
  Reverse Mutation   S. typhimurium TA98, TA100, 
TA102, TA1535, and TA1537  
1 - 1000 μg/plate [3,2] 
0.1 - 100 μg/plate [3,1] 
Negative
   Bhatia et al., 2010   Same test as Sokolowski, 
2007b 
 
[1] Without S9 metabolic activation. 
[2] With S9 metabolic activation. 
[3] Plate incorporation method. 
[4] Pre-incubation method. 
[5] With and without S9 metabolic activation. 
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Table 9:   Additional Genotoxicity Data (in vivo) Considered by the Panel in FGE.200 
Register name  
[FL-no] 
Test System in vivo   Test Object   Doses   Result   Reference   Comments 
trans-2-Hexenal  
[05.073]  
 
Micronucleus Assay   Mouse bone marrow 
polychromatic erythrocytes  
250, 500 and 1000 mg/kg bw   Negative   Honarvar, 2007a   Study design complies with OECD 
Guideline 474. 
Unscheduled DNA 
Synthesis  
Male rats hepatocytes  200 or 500 mg/kg bw   Negative   Durward, 2009   Purity and isomer were not 
specified. Study design complies 
with OECD Guideline 486. 
  Micronucleus Assay  Transgenic Muta
TMMouse 
(CD2-lacZ80/HazfBR)  
blood erythrocytes and 
reticulocytes 
120, 235 and 350 mg/kg/day  Negative  Beevers, 2013  Mice were treated by gavage for 
28 days. The dose of 350 
mg/kg/day was identified as 
MTD.Deviations from OECD 
Guideline 474 were identified. 
  Induction of lacZ
- 
mutation 
Transgenic Muta
TMMice 
(CD2-lacZ80/HazfBR) liver 
and duodenum 
120, 235 and 350 mg/kg/day  Negative  Beevers, 2013  Mice were treated by gavage for 
28 days. The dose of 350 
mg/kg/day was identified as MTD. 
Liver and duodenum were 
analysed. Study design complies 
with OECD Guideline 488. 
  Micronucleus Assay  Mouse bone marrow 
polychromatic erythrocytes  
250, 500 and 1000 mg/kg bw   Negative   Bhatia et al., 2010   Same test as Honarvar, 2007a. 
2-Nonenal 
 [05.171]  
Micronucleus Assay   Mouse bone marrow 
polychromatic erythrocytes  
500, 1000 and 2000 mg/kg bw   Negative   Honarvar, 2008   Study design complies with OECD 
Guideline 474. 
  Micronucleus Assay   Mouse bone marrow 
polychromatic erythrocytes  
500, 1000 and 2000 mg/kg bw   Negative   Bhatia et al., 2010   Same test as Honarvar, 2008a. 
2-Dodecenal 
[05.037]  
Micronucleus Assay   Mouse bone marrow 
polychromatic erythrocytes  
500, 1000 and 2000 mg/kg bw   Negative   Honarvar, 2007b   Study design complies with OECD 
Guideline 474. 
  Micronucleus Assay  Mouse bone marrow 
polychromatic erythrocytes  
500, 1000 and 2000 mg/kg bw   Negative   Bhatia et al., 2010   Same test as Honarvar, 2007b. 
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ABBREVIATIONS 
ABS     Chromosomal Aberrations 
ALDH    Aldehyde Dehydrogenase  
BrdU    Bromodeoxyuridine 
bw    body weight 
CAS    Chemical Abstract Service 
CEF    Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CoE    Council of Europe 
DNA    Deoxyribonucleic acid 
EFFA    European Flavour Association 
EFSA    The European Food Safety Authority 
EGF    Epidermal Growth Factor 
EU    European Union 
FGE    Flavouring Group Evaluation 
GSH    Glutathione 
FLAVIS (FL)  Flavour Information System (database) 
GLP    Good Laboratory Practice 
Hex-PdG  1,N
2-propanodeoxyguanosine 
HPRT    Hypoxanthine Guanine Ribosyl Transferase 
ID    Identity 
IOFI    International Organization of the Flavor Industry 
IR    Infrared spectroscopy 
JECFA   The Joint FAO/WHO Expert Committee on Food Additives 
Km    Michaelis constant 
LMA    Low Melting point Agarose 
MF    Mutation Frequency 
MN    Micronuclei 
MNBN   MicroNucleated BiNucleate cells Flavouring Group Evaluation 200 
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MS    Mass spectra 
MSDI    Maximised Survey-derived Daily Intake 
MTD    Maximum Tolerated Dose 
NMA    Normal Melting point Agarose 
NMR    Nuclear Magnetic Resonance 
No    Number 
OECD    Organisation for Economic Co-operation and Development 
PBK/D   Physiologically-Based Kinetic/Dynamic 
PCE    Polychromatic Erythrocytes 
PFU    Plaque-Forming Unit 
PUFAs   Polyunsaturated Fatty Acids 
(Q)SAR  (Quantitative) Structure Activity Relationship 
RI    Replication Index 
SCE    Sister Chromatid exchange 
SCF    Scientific Committee on Food 
TG    6-Thioguanine 
TLC    Thin-Layer Chromatography 
UDS    Unscheduled DNA Synthesis 
Vmax    Maximal Velocity 
WHO    World Health Organization 